Khavinson peptide bioregulators
Browse 52 synthetic peptides and tissue extracts. Find study methods, doses, participant counts, reported results and original sources.
Filter by preparation or study type
Findings from selected studies
- Light sensitivity in macular degeneration
In 21 people followed for 720 days, mean light sensitivity in eyes with dry macular degeneration increased 3.27 dB with Retinalamin and decreased 4.14 dB with placebo. The change in treated eyes with wet disease was inconclusive.
- Pain-free walking distance
In a randomized study of 108 patients with arterial disease, pain-free walking distance rose 46.2% and 31.4% in the two Slavinorm groups and 6.5% with placebo.
Browse preparations A–Z
52 of 52 preparations
Selected clinical studies
The St. Petersburg Institute of Bioregulation and Gerontology published work on Slavinorm development with the Pavlov Institute of Physiology and short peptides found in organ extracts. The map also includes studies from other Russian research groups.
- Retinalamin versus placebo in 21 patients with macular degeneration over two years.
- Retinalamin imaging and electrical responses in 56 patients with diabetic retinopathy.
- 90-person Prostatilen AC trial and three-month follow-up in 35 men.
- Retinalamin in 46 patients with retinal dystrophy.
- Retinalamin, Cortexin and Ventfort Lingval in 38 patients with dry AMD.
- Suprefort · 918-person type 2 diabetes comparison.
- Taxorest · 52-person bronchitis report with spirometry and a 30-day schedule.
- Glandokort · 30-day report on adrenal hormones.
- Ventfort, Cerluten, Svetinorm and Endoluten in a 1,249-person cerebral atherosclerosis comparison.
How to read the evidence
A tissue extract can contain many short peptides. Its study results apply to the whole preparation. A direct comparison is needed to establish whether an individual peptide has the same effects.
Each study lists its participants or experimental model. Translations and reprints of one study share a single entry. The two Seoul reports could share participants because their recruitment dates overlap.
A Vesugen paper has a title about circulation in the legs and an abstract about erectile dysfunction. See the publication record for the discrepancy.
Bonothyrk ↗
Named tissue preparation · Tissue extract
1 human reports
The 33-person report gives bone mineral density loss categories three months after treatment. The printed category percentages conflict with the stated group sizes.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Bonothyrk: institute clinical report (commercially hosted translation) ↗
2011 · Institute report — commercial reproduction · Oral calf parathyroid tissue polypeptide complex
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
33 women aged 47–56: 20 preparation, 13 controls
The 33-person report gives bone mineral density loss categories three months after treatment. The printed category percentages conflict with the stated group sizes.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
Bronchogen ↗
Respiratory · Synthetic peptide
1 human reports · 1 animal models · 3 cell / tissue models
In a 30-day comparison, vital capacity rose from 3,650.5 to 4,130.4 mL with oral Bronchogen plus standard care, versus 3,735.6 to 3,805.3 mL with standard care. Expiratory forced vital capacity rose from 2,740.7 to 3,800.7 mL versus 2,850.0 to 3,210.9 mL.
Studies and sources
Sequence or preparation · AEDL
Related preparation · Bronchial mucosa complex. AEDL reported in the analytical paper; sequence order should be checked against each original experiment.
Human reports
- Prospects of tetrapeptide application in treatment of chronic bronchitis: molecular mechanisms ↗
2014 · Journal publication · Oral Bronchogen capsule preparation described as AEDL
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
78 patients aged 34–65 with chronic bronchitis and an asthmatic component in remission; adjunctive Bronchogen 58, standard-care controls 20. Stratified randomization reported.
In a 30-day comparison, vital capacity rose from 3,650.5 to 4,130.4 mL with oral Bronchogen plus standard care, versus 3,735.6 to 3,805.3 mL with standard care. Expiratory forced vital capacity rose from 2,740.7 to 3,800.7 mL versus 2,850.0 to 3,210.9 mL.
Animal models
- Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology ↗
2015 · Journal publication · Defined synthetic peptide
Rats exposed intermittently to nitrogen dioxide for 60 days to model obstructive lung disease.
After one month of Bronchogen, rats showed less bronchial remodeling and neutrophilic inflammation, recovery of ciliated cells and increased secretory IgA. Numerical differences are not given in the abstract.
Cell / tissue models
- The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats ↗
2006 · Journal publication · Synthetic peptide / defined-sequence research
Heart, lung, prostate and pancreatic explants from young and old rats
Reports tissue-specific growth responses to the corresponding synthetic peptides in organotypic cultures.
- Peptides tissue-specifically stimulate cell differentiation during their aging ↗
2012 · Journal publication · Defined synthetic peptides
Human embryonic pancreatic and bronchial cell cultures, plus human prostatic fibroblasts, compared at different passage ages.
Pancragen increased differentiation-marker expression in pancreatic cells, Bronchogen in bronchial cells, and Vesugen in prostatic fibroblasts. Responses were more pronounced in aged cultures.
1 more studies
- Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. ↗
2011 · Original journal report · Defined synthetic peptides tested in cell uptake or DNA-binding assays
HeLa cells and nucleic-acid fluorescence assays
Fluorescent Epitalon, Pinealon and Testagen entered HeLa cells and nuclei. Separate fluorescence assays found sequence-dependent DNA binding, including for Bronchogen.
A 78-patient comparison reported lung-function measurements with oral capsules. Injectable AEDL and Chonluten are distinct preparations. The report describes neither a placebo nor blinding.
Composition, reviews & other sources (3)
- Identification of short peptides in the composition of polypeptide complexes isolated from animal organs ↗
2020 · Analytical / composition study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
- Bronchogen: AEDL respiratory peptide — US7625870B2 ↗
2009 · Patent publication · Patent-defined substance or composition
Cardiogen ↗
Heart · Synthetic peptide
1 animal models · 2 cell / tissue models
Cardiogen inhibited tumor growth in a dose-dependent pattern, with more tumor-cell apoptosis and hemorrhagic necrosis. The authors linked this to tumor vasculature rather than a direct cytostatic effect.
Studies and sources
Sequence or preparation · AEDR
Related preparation · Heart polypeptide complex, review-described. Analytical derivation reported in review; original characterization remains a gap.
Animal models
- Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats ↗
2009 · Journal publication · Defined synthetic peptide
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Senescent rats with transplanted M-1 sarcoma.
Cardiogen inhibited tumor growth in a dose-dependent pattern, with more tumor-cell apoptosis and hemorrhagic necrosis. The authors linked this to tumor vasculature rather than a direct cytostatic effect.
Cell / tissue models
- The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats ↗
2006 · Journal publication · Synthetic peptide / defined-sequence research
Heart, lung, prostate and pancreatic explants from young and old rats
Reports tissue-specific growth responses to the corresponding synthetic peptides in organotypic cultures.
- The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats ↗
2009 · Journal publication · Defined synthetic peptide
Myocardial explants from rats aged 3 and 24 months.
Cardiogen stimulated proliferation in heart-tissue cultures from young and old rats and reduced p53 expression. The tested concentration was 10⁻¹² M; the abstract gives no proliferation effect size.
Infarction experiment is patent-reported animal evidence. The infarction study used animals.
Composition, reviews & other sources (4)
- Peptide substance restoring myocardium function — US7662789B2 ↗
2010 · Patent / reported experiments
- Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation ↗
2023 · Review
2 more sources
- Peptidergic regulation of age-related alterations in the cardiovascular system ↗
2026 · Journal publication
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
- Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression ↗
2013 · Review
Cartalax ↗
Cartilage / renal models · Synthetic peptide
3 human reports · 3 animal models · 5 cell / tissue models
A later research lecture reports 13.5% higher bone-regenerate density with perioperative Cartalax than with controls. The original paper’s outcome tables remain unavailable.
Studies and sources
Sequence or preparation · AED / T-31
Related preparation · Cartilage polypeptide complex (PCC). AED identified analytically; shared sequence does not establish preparation equivalence.
Human reports
- Peptide bioregulators in surgical treatment of chronic periapical odontogenic infection in older adults ↗
2015 · Published clinical study; indexed abstract with separately attributed lecture methods · Named oral Cartalax product; not PCC or injectable AED
53 older dental-surgery patients, ages 61–83; 28 Cartalax recipients and 25 controls. Counts are reproduced in the 2025 research lecture, not supplied by the indexed abstract.
A later research lecture reports 13.5% higher bone-regenerate density with perioperative Cartalax than with controls. The original paper’s outcome tables remain unavailable.
- Personified prevention of diseases under the conditions of the Far North ↗
2016 · Journal publication · Risk-assigned capsule program: Endoluten tissue extract and named synthetic peptide products; Cerluten also named in assignments
113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.
1 more studies
- Cartalax clinical report: joint and spine symptoms in a 2005–2006 institute program ↗
2011 · Commercial reproduction of institute clinical report; duplicated preparation attribution · Cartalax-labeled oral product; duplicated Sigumir cohort makes attribution uncertain
Report describes 33 Cartalax recipients and 31 controls, ages 45–78, with knee osteoarthritis, spinal osteochondrosis or osteoporosis; preparation attribution is disputed by duplication within the brochure.
The Cartalax-labeled report describes pain and mobility improvement in 68.5% of knee cases and pain reduction in 53.7% of spine cases, without significant X-ray change. The same brochure repeats the cohort and percentages under Sigumir, so these figures cannot be treated as independently verified Cartalax outcomes.
Animal models
- OPTIMIZATION OF REPARATIVE OSTEOGENESIS JAWS ON AGING (PRECLINICAL STUDIES) ↗
2016 · Animal / experimental
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Old rats with standardized mandibular bone defects
Cartalax given before surgery was associated with more advanced bone remodeling at 60–120 days than control or treatment starting at surgery. Early healing was similar to control.
- Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats ↗
2015 · Animal / experimental · Injected kidney polypeptide complex, identified as Pielotax in the Russian reproduction. EDL, AED and AEDG were separate short-peptide arms.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.
Filtration rates were 433.3 with the kidney complex, 543.9 with EDL, 305.1 with AED and 469.9 with AEDG versus 240.8 µL/min with cisplatin alone. AED did not significantly improve filtration.
1 more studies
- Kidney polypeptide complex, EDL, AED and AEDG in aged rats ↗
2019 · Animal / experimental
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
35 rats aged 20–24 months. Five randomized groups of seven.
Two-hour urine output was 4.25 mL with the kidney complex, 4.40 with EDL and 4.78 with AED versus 3.51 in controls. AEDG lowered filtration to 406.22 versus 516.32 µL/min.
Cell / tissue models
- Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro ↗
2016 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Aging skin-fibroblast cultures; KE, KED, AED and AEDG
The peptides altered proliferation, remodeling and aging-associated protein markers. AED and AEDG also reduced caspase-dependent apoptosis in this model.
- Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals ↗
2015 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Kidney explants from young and old rats
Compared kidney polypeptide complex with T-31/AED and T-35/EDL. The short peptides changed proliferation and apoptosis markers, with smaller effects than the complex.
3 more studies
- [Tripeptides slow down aging process in renal cell culture]. ↗
2014 · In vitro · Preparation-specific research; no equivalence inferred
Young and aged renal cell cultures, with a separate computational DNA interaction analysis.
In young and aged renal cell cultures, the short peptides AED and EDL increased proliferation and SIRT6 expression while reducing the senescence-associated markers p16, p21 and p53.
- Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides ↗
2020 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Human embryonic bone-marrow MSC line FetMSCs, aged in culture
AED, KED and KE changed expression of selected aging-related genes. Effects depended on peptide and culture-aging model; KED affected TNKS2 in opposite directions across models.
- Effect of short peptides on neuronal differentiation of stem cells ↗
2019 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Human periodontal-ligament stem-cell cultures
Examined AED, KED, KE, AEDG and their mixture. Increased neuronal-marker expression was reported for KED and the mixture.
The dental study and knee patent describe different comparisons. The brochure repeats Sigumir outcomes under Cartalax. The 2022 jaw-joint abstract leaves the preparation unnamed.
Composition, reviews & other sources (6)
- AED bone/cartilage composition and reported knee-osteoarthritis comparison — RU2299741C1 ↗
2007 · Patent / reported experiments
- Bioregulation therapy in age-related osteoarthropathy of the temporomandibular joint ↗
2022 · Related human jaw-joint report; Cartalax methods await full-text verification
4 more sources
- Identification of short peptides in the composition of polypeptide complexes isolated from animal organs ↗
2020 · Analytical / composition study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
- Peptide Regulation of Chondrogenic Stem Cell Differentiation ↗
2023 · Review
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
- Short Peptides Regulate Gene Expression ↗
2016 · Computational mechanism study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
- Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression ↗
2013 · Review
Sources with open questions (1)
- PCC osteoarthritis Phase II program — original trial recovery target ↗
Trial not recovered · link is to the citing review
Cerluten ↗
Named tissue preparation · Tissue extract
5 human reports
The 2005–2006 report describes attention-test and selected EEG improvements during 10–20 days of adjunctive treatment.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Cerluten: clinical report on a tissue-derived preparation ↗
2006 · Institute report — commercial reproduction · Tissue-derived mixture / named preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
85 patients: 48 adjunctive Cerluten; 37 conventional-care controls. Mixed neurological diagnoses.
The 2005–2006 report describes attention-test and selected EEG improvements during 10–20 days of adjunctive treatment.
- Personified prevention of diseases under the conditions of the Far North ↗
2016 · Journal publication · Risk-assigned capsule program: Endoluten tissue extract and named synthetic peptide products; Cerluten also named in assignments
113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.
3 more studies
- Suprefort with and without Cerluten and Endoluten in type 2 diabetes ↗
2013 · Conference report · company reproduction · Oral pancreas, brain and pineal polypeptide preparations added to standard therapy
918 adults aged 52–65 with type 2 diabetes: 329 standard care, 214 added Suprefort, 375 added Suprefort, Cerluten and Endoluten.
The conference report lists two-hour glucose of 9.7 mmol/L with standard care, 7.3 with added Suprefort, and 6.5 with the three-product combination.
- Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis ↗
2013 · Conference report · company reproduction · Oral vascular, brain, liver and pineal polypeptide preparations added to standard therapy
1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.
The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.
- Oral Cerluten with injected Cortexin in older women with vascular encephalopathy ↗
2007 · Dissertation author abstract · Oral Cerluten tablets (also named Ceremax in the author abstract) and intramuscular Cortexin.
167 women aged 65–74 with stage II dyscirculatory encephalopathy. Usual care 68, usual care plus Cortexin 45, usual care plus Cortexin and Cerluten 54.
At days 30–31, psychosomatic severity scores were 18.04 with Cerluten plus Cortexin, 24.13 with Cortexin alone as an adjunct, and 30.49 with usual care. All three groups improved.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
Chelohart ↗
Named tissue preparation · Tissue extract
1 human reports · 1 cell / tissue models
Angina occurred during exercise testing in 36.4% with Chelohart and 50% with conventional care. Threshold exercise power did not differ significantly between groups.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Chelohart: clinical report on a tissue-derived preparation ↗
2011 · Institute report — commercial reproduction · Tissue-derived mixture / named preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
32 angina patients: 22 adjunctive Chelohart; 10 controls.
Angina occurred during exercise testing in 36.4% with Chelohart and 50% with conventional care. Threshold exercise power did not differ significantly between groups.
Cell / tissue models
- [POLYPEPTIDES INFLUENCE ON TISSUE CELL CULTURES REGENERATION OF VARIOUS AGE RATS]. ↗
2015 · Original journal report
Organotypic tissue cultures from young and old rats
Calf-tissue preparations, including Ventvil, stimulated corresponding tissue-culture growth with changes in proliferation-related markers.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
Chitomur ↗
Bladder · Tissue extract
2 human reports
Post-course peak urinary flow was 12.7 vs 9.4 mL/s and prostate symptom scores were 13.2 vs 15.6 with Chitomur versus placebo. Prostate volume showed no significant change.
Studies and sources
Sequence or preparation · Urinary bladder peptide preparation
Related preparation · Bladder-derived peptide preparation. The original clinical reports named oral Chitomur.
Human reports
- Oral Chitomur versus capsule placebo in men with benign prostatic hyperplasia ↗
2013 · Journal article — commercial reproduction · Oral calf bladder-derived peptide preparation.
50 men aged 62–83 with benign prostatic hyperplasia. Chitomur 30, capsule placebo 20.
Post-course peak urinary flow was 12.7 vs 9.4 mL/s and prostate symptom scores were 13.2 vs 15.6 with Chitomur versus placebo. Prostate volume showed no significant change.
- Oral Chitomur versus usual treatment in women with overactive bladder ↗
2013 · Journal article — commercial reproduction · Oral bladder tissue peptide preparation.
50 women aged 48–80 with overactive bladder. Chitomur 30, usual care 20.
Urgency episodes fell from 4.05 to 2.83 with Chitomur and from 4.62 to 3.11 with usual care around day 15. Later counts were 3.26 and 2.67, respectively.
The separate studies assessed lower urinary tract symptoms in men and overactive bladder in women.
Chonluten ↗
Respiratory · Synthetic peptide
1 human reports · 2 cell / tissue models
The report lists forced expiratory vital capacity of 3,800.8 mL after adjunctive Chonluten versus 3,200.7 mL after conventional care. It marks the former against a shared baseline of 2,850.6 mL.
Studies and sources
Sequence or preparation · EDG
Related preparation · Bronchial mucosa complex. EDG reported in analytical work; product characterization is a separate question.
Human reports
- Chonluten in chronic bronchitis: Medical Center clinical report ↗
2006 · Institute report / commercial reproduction · Oral Chonluten as described in the report
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
42 adults aged 38–65 with chronic bronchitis and an asthmatic component: 23 received adjunctive Chonluten and 19 received conventional therapy.
The report lists forced expiratory vital capacity of 3,800.8 mL after adjunctive Chonluten versus 3,200.7 mL after conventional care. It marks the former against a shared baseline of 2,850.6 mL.
Cell / tissue models
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line ↗
2022 · Journal publication · Defined peptides and Thymalin peptide complex tested separately
THP-1 leukemia-derived monocytes, differentiated macrophages and an activated HUVEC endothelial adhesion model.
Five preparations reduced LPS-induced TNF and IL-6 expression in differentiated THP-1 cells and reduced adhesion to activated endothelial cells. Chonluten also reduced monocyte TNF release; the full text notes an apoptotic cell fraction with Chonluten.
- EDG at 1 ng/mL in rat lung, bronchial and arterial explants ↗
2025 · In vitro · Defined Glu–Asp–Gly (EDG, Chonluten), a sequence detected in the bronchial extract. The experiment used the individual peptide.
Three-month-old Wistar rats provided 230 lung, 200 bronchial and 210 bronchial artery explants across all experiments. Each dish contained 18–20 explants. The report does not give EDG-specific counts or the number of donor rats.
At 1 ng/mL, EDG increased the lung explant area index by 21 ± 3% versus control. The index rose by 3 ± 1% in bronchial and bronchial artery cultures, with neither change statistically significant.
Institute product report is not a trial of independently characterized EDG. Chonluten and Bronchogen are different entries.
Composition, reviews & other sources (2)
- Identification of short peptides in the composition of polypeptide complexes isolated from animal organs ↗
2020 · Analytical / composition study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
- Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression ↗
2013 · Review
Cortagen ↗
Brain · Synthetic peptide
6 animal models · 2 cell / tissue models
Cortagen increased regenerating nerve growth rate and conduction velocity in the rat experiment.
Studies and sources
Sequence or preparation · AEDP
Related preparation · Brain-peptide program; direct product derivation unresolved. Shared tissue tradition, not verified identity with Cortexin.
Animal models
- Effect of tetrapeptide cortagen on regeneration of sciatic nerve. ↗
2000 · Original journal report
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Rats after sciatic-nerve transection and suture
Cortagen increased regenerating nerve growth rate and conduction velocity in the rat experiment.
- [Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia]. ↗
2011 · Original journal report
Rats with experimental chronic brain ischemia
Cortagen and Cortexin accelerated recovery of disturbed behavior and reduced oxidative-stress changes.
4 more studies
- Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray ↗
2004 · Journal publication · Defined synthetic peptide
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Female 6-month-old CBA mice given Cortagen injections for five days; cardiac gene-expression assay.
Cortagen changed 234 of 15,247 assayed cardiac transcripts (1.53%), matching 110 known genes. Maximum reported changes were 5.42-fold up and 2.86-fold down.
- Age and baseline anxiety in Lysenko’s peptide stress models ↗
2006 · Doctoral dissertation, 244 pp., introduction and conclusions
Rats grouped by age and baseline anxiety; series-specific denominators remain unverified.
The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.
- Oleyl-Cortagen versus Cortagen: central and systemic rat assays ↗
2015 · Dissertation · Oleyl-Ala–Glu–Asp–Pro is lipid-modified Cortagen. Cortexin and Cerebrolysin were separate tissue peptide comparators.
496 Wistar rats (200–220 g) across several behavioral experiments; not the denominator for a single comparison
In Table 4, Oleyl-Cortagen increased hypothalamic self-stimulation at the smallest central dose. The response weakened at higher central doses. Cortagen, Cortexin and Cerebrolysin showed different dose patterns.
- Shabanov’s rat peptide behavior comparison: Oleyl-Cortagen and Cortexin ↗
2009 · Original journal article
192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery
Oleyl-Cortagen and Cortexin increased hypothalamic self-stimulation by 32% and 23%, respectively. Cortagen and Cerebrolysin did not change this outcome; other behavioral assays differed.
Cell / tissue models
- Effects of short peptides on thymocyte blast transformation and signal transduction along the sphingomyelin pathway. ↗
2002 · Original journal report
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Mouse thymocytes
Vilon stimulated thymocyte proliferation most strongly; Epitalon was less active and Cortagen showed no such effect.
- Effects of short peptides on lymphocyte chromatin in senile subjects ↗
2004 · Journal publication · Defined synthetic peptides
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Leukocytes sampled from people aged 75–88 years and exposed to peptides in culture.
Five short peptides increased ribosomal-gene activity and altered condensed chromatin in sampled leukocytes. Epitalon, Livagen and Prostamax changed chromosome-1 pericentromeric chromatin; Epitalon and Livagen also changed chromosome 9.
Rat studies measured nerve recovery and experimental brain ischemia. Cortagen was inactive in the linked thymocyte proliferation assay; human efficacy remains unestablished.
Composition, reviews & other sources (4)
- Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression ↗
2013 · Review
- 2026 European publication: modified GHK, Epitalon, Semax, Selank and Cortagen analogues — EP4758157A1 ↗
2026 · Patent publication · Patent-defined substance or composition
2 more sources
- Cortagen: AEDP molecular and neuronal-use claims — US7189701B1 ↗
2007 · Patent publication · Patent-defined substance or composition
- Neuroprotective effects of peptides bioregulators in people of various age ↗
2013 · Review
Sources with open questions (1)
- Cortagen neurological patent examples ↗
Lead · original evidence not verified
Cortexin ↗
Brain · Tissue extract
65 human reports · 21 animal models · 3 cell / tissue models
Double-blind placebo-controlled comparison of repeated Cortexin, one course followed by placebo, and placebo. Authors reported functional and pharmacoeconomic benefits.
Studies and sources
Sequence or preparation · Mixture
Related preparation · Brain-derived preparation. Clinical formulation distinct from Pinealon and Cortagen.
Human reports
- Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke ↗
2014 · Randomized trial
ESCORT; 272 acute ischemic-stroke patients
Double-blind placebo-controlled comparison of repeated Cortexin, one course followed by placebo, and placebo. Authors reported functional and pharmacoeconomic benefits.
- An open clinical trial of cortexin in treatment of brain ischemia ↗
2014 · Uncontrolled human report
Analysis of 500 patients with stage II brain ischemia
The authors describe before/after cognitive, affective, and neurological changes in an open treatment analysis.
63 more studies
- Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration ↗
2021 · Original journal report · Temporal paravascular Retinalamin injections with or without Cortexin and Ventfort Lingval by electrophoresis
38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.
Visual acuity went from 0.71 to 0.76 with Retinalamin alone and from 0.76 to 0.88 with the combination. This comparison used electrophoresis for the two added preparations.
- Cortexin after a first ischemic stroke: 12-month cognitive follow-up ↗
2013 · Randomized trial
80 patients after first ischemic stroke, 40 with Cortexin plus standard care and 40 with standard care alone.
At six months, 18/40 Cortexin recipients and 33/40 controls met the MoCA impairment threshold. At baseline the counts were 27/40 and 32/40. The paper reported significant between-group comparisons from months 6 through 12.
- One or two Cortexin courses after stroke: cognitive outcomes in a 90-patient comparison ↗
2016 · Human comparative study
90 patients with hemispheric ischemic stroke admitted within 24 hours. Three arms of 30.
The authors reported the largest cognitive improvements after two courses. On MMSE, the two-course group showed an earlier advantage over standard care than the single-course group.
- Oral Cerluten with injected Cortexin in older women with vascular encephalopathy ↗
2007 · Dissertation author abstract · Oral Cerluten tablets (also named Ceremax in the author abstract) and intramuscular Cortexin.
167 women aged 65–74 with stage II dyscirculatory encephalopathy. Usual care 68, usual care plus Cortexin 45, usual care plus Cortexin and Cerluten 54.
At days 30–31, psychosomatic severity scores were 18.04 with Cerluten plus Cortexin, 24.13 with Cortexin alone as an adjunct, and 30.49 with usual care. All three groups improved.
- Cortexin, shooting and race performance in biathletes ↗
2014 · Scientific Notes of Lesgaft University. 12(118):210–213
20 biathletes, 10 Cortexin and 10 placebo.
The paper reports 26% fewer shooting misses in the Cortexin arm after ten days, 5.6% faster course speed and a 5.5% versus 2.9% increase in an integrated work-capacity score.
- Four intranasal peptide arms at simulated 4,500 m ↗
2014 · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12
Men aged 20–25 with asthenic or immune-status features. Four active arms of 6–8 each and 11 saline controls.
Thymogen was associated with lower lactate during the chamber protocol. Cortexin showed longer complex reaction latency alongside other physiological changes. The endpoints were heterogeneous.
- Cheprasov’s Medilab peptide comparisons in aerospace stress ↗
1997 · Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods
116 men across three stress comparisons (30, 70 and 16), plus an eight-cosmonaut comparison within the reported dissertation program of 328.
The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.
- Cortexin and other adjuncts in military combined-injury rehabilitation ↗
2008 · Kirov Military Medical Academy candidate dissertation author abstract
317 screened, 76 selected (61 men and 15 women), 60 analyzed in four groups of 15. Sixteen early discharges.
Reported work-capacity scores rose from 516.0 to 569.3 with Cortexin and from 524.1 to 613.2 with Vinpotropil. Standard care fell from 526.1 to 509.8.
- Savchenko’s naval rehabilitation Cortexin comparison ↗
2006 · Doctoral dissertation, Psychophysiological correction of psychosomatic disorders in military personnel, conclusion 10
Military officers and retired personnel in a rehabilitation program. Cortexin-comparison arm denominators unresolved.
The author reported a recovery index of 80.5 versus 71.6 in the control group. Physical work capacity normalized in 50% in both groups.
- Cortexin and blood chemistry in elite swimmers ↗
2021 · Lesgaft University proceedings, printed pp. 8–11
14 national-team swimmers aged 20–23, seven in each arm.
Blood urea fell in both groups and fell more with saline in the reported comparison. Race-time benefit was not measured.
- Intranasal Cortexin and statokinetic tolerance in volunteers ↗
2014 · Reviews on Clinical Pharmacology and Drug Therapy 12(4):67–71
86 healthy men aged 18–20 screened. Thirty-two with baseline tolerance below two minutes entered the Cortexin or saline comparison.
The authors reported 1.40–1.44-fold changes on selected stabilography measures and longer motion tolerance. The findings do not measure brain uptake.
- Cortexin in 187 patients with prior brain injury ↗
2004 · Bulletin of the Russian Military Medical Academy, 2004(2):74–76; parallel report with outcome table
187 patients aged 19–56, 107 injured during combat. Severity analysis included 117 less severe and 70 severe injuries.
The authors classified 95 outcomes as good and 62 as satisfactory. Thirty were unsatisfactory. Less-severe injuries had more favorable results.
- Epitalon and Cortexin after acute systemic cold injury ↗
2009 · Candidate dissertation author abstract, Tables 1–3
Hospitalized cold-injury patients. Three adjunct arms had 25 patients each. The severity-specific outcome tables use smaller subgroups.
In the severe-injury table, day-five neuron-specific enolase was 23.2 ng/mL with both agents and 58.9 ng/mL with standard care. No formal interaction analysis was reported.
- EMERCOM proceedings: four drugs in a 217 km military field exercise ↗
2016 · Original conference abstract
320 Belarusian contract servicemen, mean age 21.3, across four treatment groups and placebo.
During a 217 km, seven-day exercise, the authors report faster recovery with Metaprot and higher circulatory and respiratory reserves with Cortexin.
- Ganapolsky climate chambers: Cortexin, Noopept and related comparators ↗
2008 · Original dissertation author abstract
301 men aged 20–24 across the full program. Selected tables compare 17 Cortexin, 18 Noopept, 17 Cerebrolysin and nine placebo participants, with historical controls in cold.
In cold, Cortexin participants averaged 210 W versus 162 W with placebo. In heat, Noopept averaged 188 W versus 152 W with placebo.
- Ganapolsky’s 86-man climate-chamber conference report ↗
2007 · Original conference abstract
86 healthy men aged 18–22, considered fit for military service; Tabai climate chamber with cold, heat and simulated altitude
The abstract reports Dilept anxiety changes in cold, Noopept arithmetic-task findings in heat, and qualitative Cortexin work-capacity changes at simulated altitude.
- Cortexin in radiation-accident responders: Bioregulation follow-up ↗
2009 · Dissertation
165 Chernobyl response workers in the reported three initial groups (55, 50 and 60); five follow-up subgroups after repeat-course selection
At 12 months, reported memory complaints in the two 20-day-course group fell from 93.3% to 33.3%, versus 93.3% to 91.7% in the comparison group. Repeat-course selection limits attribution.
- Application of Cortexin to enhance human statokinetic resistance ↗
2002 · Original human journal publication · Intranasal Cortexin combined with multisensory/vestibular training; not PPK-V
Human statokinetic-resistance experiment; participant and group counts not supplied by the abstract
The publisher abstract reports improved statokinetic resistance after ten days of nasal Cortexin plus active sensory/vestibular training. It supplies no numerical treatment effect or denominator.
- Cortexin and childhood autism: Larkina and Khaletskaya’s preschool comparison ↗
2014 · Human comparative study
130 children aged 4–6 with language delay: 45 with residual organic brain disorders, 45 with ADHD, and 40 reported with early childhood autism. The printed autism treatment-arm counts are inconsistent with 40.
At three months, the Cortexin autism arm showed changes on selected word-association tasks. Overall speech development (p = 0.119) and social communication (p = 0.058) did not reach statistical significance.
- Cortexin in a longitudinal study of severe atypical autism ↗
2008 · Uncontrolled human report
80 selected children followed for 7–10 years from an initial clinical sample of 370, across several diagnoses under historical classifications.
The authors described clinical trajectories over 7–10 years. Cortexin was among several drugs used in individualized care. The report gave no Cortexin-specific outcome or treated denominator.
- Cortexin plus citicoline after spinal-cord injury: the 90-day Phoenix comparison ↗
2026 · Original clinical journal publication · Cortexin plus Recognan (citicoline), added to rehabilitation; not Cortexin monotherapy
60 adults aged 18–55 after gunshot-related spinal-cord injury; four groups defined by ASIA A/C severity and treatment
At day 90, the combination groups had larger reported improvements in cognition, depression and fatigue than standard care. In the ASIA A stratum, at least 50% depression-score reduction occurred in 90% versus 20%.
- Cortexin and citicoline in persistent postural-perceptual dizziness: three-group observation ↗
2025 · Original clinical journal publication · Adjunctive Cortexin with or without Recognan (citicoline); escitalopram in all groups
60 patients; 20 escitalopram plus Cortexin, 20 escitalopram plus Cortexin/citicoline, 20 escitalopram alone
All groups reported less dizziness, anxiety and insomnia; the authors described the strongest changes with the combined adjuncts. The abstract does not provide numerical post-treatment group differences.
- Molecular mechanisms and pharmacological support of adaptation to professional activity in extreme conditions ↗
2016 · Original dissertation text on institute host
570 overall in methods; a stated second stage of 320 in Chapter 5; Table 49 adds to 310. Cortexin totals 55 in the table versus 65 in the chapter. Denominators unresolved.
Visually checked tables suggest functional recovery signals and limited Cortexin metabolic recovery, but participant counts and statistical reporting conflict. Drug–placebo superiority is not established.
- Cortexin in a Russian chronic fatigue syndrome comparison ↗
2010 · Human comparative study
78 adults aged 19–46 with author-defined CFS, 56 adjunctive Cortexin and 22 comparison
Clinical ratings in the Cortexin arm · 43/56 (77%) rated good, 11/56 (20%) satisfactory and 2/56 (4%) unsatisfactory. The corresponding distribution for the 22 comparison patients was not supplied.
- Endonasal Cortexin for chronic fatigue syndrome: Melnikova dissertation and companion reports ↗
2010 · Dissertation excerpts and companion publications
The 2017 paper reports 100 adults aged 28–45 with historical CFS, mean age 31.5 ± 4.8 years. The arms were Cortexin electrophoresis (50), endonasal galvanization alone (25), and sham (25).
Author-rated improvement in the 100-person comparison · 88% with Cortexin electrophoresis, 60% with galvanization alone and 44% with sham, as summarized in 2013.
- Endonasal Cortexin for chronic fatigue syndrome: 2020 conference abstract ↗
2020 · Conference abstract
100 patients labeled CFS: 50 Cortexin electrophoresis, 25 endonasal galvanization, 25 sham procedure
EEG and cognition · Authors reported increased alpha-wave amplitude, lower abnormal delta-wave amplitude and improved cognitive test performance. The abstract supplies no numerical effects.
- Neurocognitive characteristics in children with sluggish cognitive tempo ↗
2026 · Journal publication
40 children ages 12–14 with sluggish cognitive tempo; comparison groups of 30 with combined ADHD and 30 healthy children.
After Cortexin treatment, the authors reported improvement in attention, working memory, fatigue symptoms and reading skills in 82% of cases in the sluggish-cognitive-tempo group. EEG changes accompanied the clinical observations. ADHD and healthy children were diagnostic reference groups, not randomized untreated children with the same condition.
- [Cortexin in the comprehensive treatment of neurological complications of type 2 diabetes mellitus. (Results of the DIACORT multicenter randomized clinical trial)]. ↗
2026 · Original clinical journal publication
110 randomized; 109 completed: 54 adjunctive Cortexin, 55 comparison
DIACORT reports day-90 cognitive and neuropathy differences in 109 completers; one earlier depression comparison was nonsignificant.
- [Evaluation of the efficiency of combined neuroprotection and high-intensity magnetotherapy in the medical rehabilitation of patients with ischemic stroke]. ↗
2026 · Human comparative study · Cortexin-containing rehabilitation regimens; one intervention group also received citicoline (Recognan), with high-intensity magnetotherapy. This is not a comparison of isolated Cortexin alone.
98 patients undergoing ischemic-stroke rehabilitation; groups of 34, 33 and 31
The authors reported greater short-term improvement in rehabilitation measures with Cortexin-containing regimens and high-intensity magnetotherapy than with standard treatment. One intervention group also received citicoline.
- [Efficacy of adding transcranial electrical stimulation to monopharmacotherapy in post-COVID syndrome with chronic fatigue and cognitive decline]. ↗
2025 · Human comparative study
150 patients with post-COVID fatigue and cognitive decline; 75 per group
The authors favored adding transcranial electrical stimulation to Cortexin for post-COVID fatigue and cognitive outcomes.
- [Proinflammatory cytokines - as a marker of the effectiveness of neuroprotection in children with perinatal nervous system damage]. ↗
2025 · Human comparative study
146 infants with perinatal nervous-system injury, divided by severity and treatment
The report describes lower proinflammatory cytokine levels with Cortexin-containing care, particularly in the severe-injury subgroup.
- [Cortexin in the comprehensive therapy of alcoholic encephalopathy]. ↗
2026 · Uncontrolled human report
40 patients with alcoholic encephalopathy; two Cortexin-dose groups
Cognitive test scores improved over ten days in both Cortexin groups during combined detoxification, metabolic and hepatoprotective care.
- New possibilities of neuroprotection in the treatment of ischemic stroke ↗
2008 · Clinical trial / comparison
62 acute hemispheric ischemic-stroke patients; 32 Cortexin and 30 placebo; treatment started within six hours
The double-blind multicenter report described improvement in neurological and functional scales compared with placebo.
- Use of cortexin in the early rehabilitation period of ischemic stroke of moderate severity ↗
2009 · Human comparative study
68 early-rehabilitation patients; 35 adjunctive Cortexin, 33 basic therapy
Motor and cognitive outcomes favored adjunctive Cortexin over basic therapy during short follow-up.
- Efficacy of Korteksin in acute period of hemispheric ischemic stroke ↗
2018 · Human comparative study
122 ischemic-stroke patients in four groups (30, 30, 30 and 32)
The authors reported the greatest neurological improvement in one repeated-course group.
- Cortexin in the complex treatment of post stroke epilepsy ↗
2010 · Human comparative study
46 patients with post-stroke epilepsy; 29 adjunctive Cortexin, 17 basic treatment
The report describes improved clinical effects and EEG findings alongside anti-seizure treatment.
- Comparative analysis of efficacy of certain neuroprotectors in ischemic stroke ↗
2006 · Human comparative study
Two comparative series: 35 patients in a Cortexin–Nootropil comparison and 45 in a Cortexin–Cerebrolysin comparison
Authors described broadly similar clinical effects in moderate ischemic stroke and some practical advantages for Cortexin.
- Effect of Cortexin on neuroplasticity in multiple sclerosis ↗
2009 · Uncontrolled human report
20 adults with relapsing-remitting MS in stable remission; 7 men and 13 women, ages 27–43
Depression and quality-of-life scores improved in an open MS cohort; the disability score did not change significantly.
- Neuropeptide immunocorrection in patients with multiple sclerosis ↗
2025 · Human comparative study · Cortexin tissue-derived peptide preparation
63 adults with MS, ages 18–59: 33 standard therapy plus Cortexin; 30 standard therapy alone
After three courses, the authors report upper-limb motor-score gains of 1.4 versus 0.8 points and lower-limb gains of 1.8 versus 0.9, with reported p<0.05. The proportion described as having reduced work capacity fell from 71.7% to 31.1% with adjunct Cortexin, versus 75.5% to 53.1% in controls. These are reported functional signals, not evidence of disease modification.
- Cortexin effectiveness in circulatory encephalopathy ↗
1999 · Human comparative study
76 patients with dyscirculatory encephalopathy: 45 adjunctive Cortexin, 31 standard care
Reports neurological and cognitive changes with nasal-electrophoresis delivery alongside standard care.
- Efficacy of cortexin in acute and recovery periodes of hemispheric ischemic stroke ↗
2016 · Human comparative study
90 patients with hemispheric ischemic stroke, 30 per arm.
Compares one course, repeated courses and basic therapy, using neurological, mobility and cognitive scales. Authors reported greater improvement with repeated treatment.
- Post-stroke cognitive impairment in young patients ↗
2024 · Uncontrolled human report
30 post-stroke adults aged 18–45
Open prospective report of cognition and quality-of-life changes during follow-up.
- Therapeutic equivalence of intravenous and intramuscular dosage forms of Cortexin in ischemic strokes ↗
2025 · Randomized trial
490 stroke patients: 246 IV-first, 244 IM; double-dummy active comparison
Compares routes of active Cortexin administration. Both groups received active drug; the placebo injections maintained masking.
- Effects of neuroprotector cortexin on the dynamics of neuroendocrine system parameters in patients with organic emotionally labile (asthenic) disorders ↗
2013 · Human comparative study
Patients with organic emotionally labile/asthenic disorders
Reports endocrine changes alongside clinical improvement when Cortexin was added to standard treatment.
- Сlinical and physiological characteristics and therapy asthenic disorders in adolescents girls ↗
2017 · Uncontrolled human report
75 adolescent girls aged 14–17 with neurasthenia
Reports symptom and EEG changes during treatment; healthy peers supplied a physiological reference.
- Working ability of elderly university teachers under the combined influence of breathing exercises and peptide bioregulator «Cortexin» ↗
2020 · Human comparative study
Older university teachers; breathing exercises plus Cortexin versus pharmacological treatment alone
Reports functional-state and professional-performance changes with combined treatment.
- Determination of the prevalence of postcovid syndrome and assessment of the effectiveness of the drug Cortexin in the treatment of neurological disorders in patients with postcovid syndrome. Results of the multicenter clinical and epidemiological observational program CORTEX ↗
2022 · Uncontrolled human report
CORTEX post-COVID program; 979 patients
Observational follow-up recorded fatigue, cognitive and other post-COVID complaints and changes during treatment.
- Results of a multicenter observational program to evaluate the effectiveness of complex therapy of patients with chronic cerebrovascular pathology with cognitive impairment with Cortexin and Neuromexol (CORNELia study) ↗
2023 · Uncontrolled human report
CORNELia; 801 patients with chronic cerebral ischemia and cognitive impairment
Reports clinical changes with Cortexin plus Neuromexol; biomarkers were assessed in smaller comparison subgroups.
- Efficacy and safety of Cortexin as additional therapy in patients with depressive disorder ↗
2026 · Human comparative study
98 patients with depression; 48 adjunctive Cortexin and 50 antidepressant-only, 28 days
Reports differences in depression, social-function and adverse-effect ratings between treatment groups.
- Efficacy of cortexin in the treatment of memory disorders in children ↗
2011 · Human comparative study
60 children with memory disorders
Compared Cortexin with encephabol and reported changes on neuropsychological and neurophysiological measures.
- The changes in the brain's electrical activity in children with cerebral palsy during the complex rehabilitation ↗
2012 · Human comparative study
105 children with spastic diplegia cerebral palsy
Three rehabilitation groups compared microcurrent treatment, microcurrent plus Cortexin, and standard care; functional and EEG changes were reported.
- Peptidergic nootropic therapy in cerebral palsy associated with epilepsy ↗
2017 · Uncontrolled human report
84 children with cerebral palsy and epilepsy
Adjunctive Cortexin with antiseizure medicines was associated with varied motor and seizure outcomes; one seizure aggravation was reported.
- Results of a multicenter study on the efficacy of cortexin in treatment of cognitive dysfunction in children ↗
2018 · Uncontrolled human report
635 children aged 3–7 across four diagnostic groups
Reports before/after attention, memory and thinking changes across ADHD, speech-delay, perinatal-injury and asthenic/neurotic groups.
- Potential of peptidergic nootropic therapy in developmental dysphasia in children ↗
2019 · Randomized trial
54 children aged 3–4 with developmental dysphasia
Randomized comparison with no drug treatment reported speech and parent-questionnaire changes over two months.
- Developmental dysphasia in children: a comparison of the effectiveness of two modes of peptidergic nootropic therapy ↗
2020 · Human comparative study
94 children aged 3–4 with developmental dysphasia
Compares one course, two courses and no medication over two months; reports vocabulary and phrase-use changes.
- Treatment of contusion of moderate severity in children in outpatient clinics ↗
2020 · Human comparative study
74 children aged 6–13 with moderate brain contusion
A 74-child brain-contusion comparison reported recovery in both groups and favorable cognitive/EEG findings with adjunctive Cortexin, without numerical group differences in the abstract.
- Executive functions disorders in children with dyslexia ↗
2021 · Human comparative study
60 children with dyslexia; 60 healthy reference children
Thirty treated patients received Cortexin and thirty encephabol; reading, attention and memory changes were reported.
- The effectiveness of rehabilitation measures using the drug Cortexin in children with neuropsychiatric pathology ↗
2024 · Human comparative study
Infants with hypoxic neurological pathology; denominators unresolved
Reports adjunctive rehabilitation and EEG outcomes during one-year follow-up.
- Cognitive disturbances in children with chronic tics and their treatment ↗
2019 · Human comparative study
50 children with chronic motor tics; separate transient-tic and healthy reference groups
Compared phenibut with phenibut plus Cortexin and reported symptom/cognitive differences.
- Cortexin administration due to improvement of cognitive and behavioral disorders in children and teenagers with epilepsy ↗
2021 · Uncontrolled human report
86 children and adolescents with epilepsy
In an 86-person pediatric epilepsy report, cognitive improvement was reported in 65% and no seizure aggravation in 95% during adjunctive Cortexin use.
- Meteoadaptogenic properties of peptide drugs in healthy volunteers ↗
2007 · Clinical trial / comparison
127 healthy men aged 20–24 across a three-day environmental program; active groups reported as 10–20, placebo 8–10 per stage
Noopept showed different performance and anxiety results under cold, heat and simulated altitude. The tables also distinguish Cortexin, Dilept and Vinpotropil.
- Meteoadaptogenic properties of nootrop drugs ↗
2007 · Human comparative study
Healthy men aged 20–24; −10°C, +45°C and hypoxia (reported pO₂ 109.9 mmHg)
The Academy abstract describes stressor-specific functional-state findings across four compounds, including Noopept. It emphasizes mental work capacity and heat/high-altitude adaptation.
- CHRONAS: pilot study of chronic sleep disorders in patients with chronic cerebral ischemia ↗
2024 · Uncontrolled human report
50 patients with chronic cerebral ischemia and comorbidities
Prospective pilot report using sleep, sleepiness and other clinical questionnaires. The abstract describes changes after treatment, but does not describe a randomized untreated control.
Animal models
- Thymogen and four peptide preparations in hypoxia, heat and cold ↗
2018 · Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11
Outbred male mice in the single-dose hypoxia screen; male rats (180–210 g) in the repeated-dose hypoxia table. Separate temperature experiments.
In the three-day rat comparison, Thymogen at 0.1 mg/kg gave 28.6±11.8 min versus 2.2±0.1 with saline. All 16 arms and their reported values match the 2014 monograph. Thymogen had no significant benefit on the air-cooling endpoint.
- Cortexin and Dalargin during a 21-day rat swimming series ↗
2014 · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 5, pp. 148–151, Table 9
Rats in separate Cortexin, Dalargin and control arms. Per-arm n remains unconfirmed.
First-swim means reached 227.25 s with Cortexin and 218.0 s with Dalargin on day 21, versus 71.9 s in controls. Starting means already differed.
19 more studies
- Intranasal carrier and injected Cortexin in rat seizure models ↗
2011 · Original journal article, methods and Figures 1–4
180 male Wistar rats across three experiment designs, six groups of 10 per design.
The intranasal carrier arm did not reproduce the significant delayed effect seen at 1.0 mg/kg intraperitoneally.
- Blinded rat stroke comparison of four peptide preparations ↗
2019 · Journal of the Neurological Sciences 398:22–26
Male Wistar rats with embolic middle cerebral artery occlusion, 23 initially randomized per arm; early deaths excluded from analysis.
Only Cerebrolysin improved measured functional outcomes versus saline. The other hydrolysates had no significant functional effect and no treatment reduced lesion volume significantly.
- Cortexin and Semax in a prolonged rat cold-stress model ↗
2022 · Pediatrician 13(6):85–96
90 outbred male rats (180–220 g), with 30 each in the placebo, Cortexin and Semax groups.
Day-14 swim time was 3.2±0.1 min with Semax and 1.3±0.1 min with either saline or Cortexin. The 35°C plateau lasted 10, 12 and 14 days across the three groups.
- Kim’s five-peptide comparison in animal stress experiments ↗
2024 · Dissertation
Separate animal pharmacology experiments; participant-level and group-level counts for the five preparations unavailable
The chapter identifies Cortexin, Pineamin, Prostatilen, Thymalin and Thymogen. The author highlights Pineamin in conclusions; original outcome tables and dose schedules have not been recovered.
- Oleyl-Cortagen versus Cortagen: central and systemic rat assays ↗
2015 · Dissertation · Oleyl-Ala–Glu–Asp–Pro is lipid-modified Cortagen. Cortexin and Cerebrolysin were separate tissue peptide comparators.
496 Wistar rats (200–220 g) across several behavioral experiments; not the denominator for a single comparison
In Table 4, Oleyl-Cortagen increased hypothalamic self-stimulation at the smallest central dose. The response weakened at higher central doses. Cortagen, Cortexin and Cerebrolysin showed different dose patterns.
- Shabanov’s rat peptide behavior comparison: Oleyl-Cortagen and Cortexin ↗
2009 · Original journal article
192 Wistar rats, 200–220 g; methods describe at least 10–12 per group across a behavioral test battery
Oleyl-Cortagen and Cortexin increased hypothalamic self-stimulation by 32% and 23%, respectively. Cortagen and Cerebrolysin did not change this outcome; other behavioral assays differed.
- Cortexin in rat seizure models: nanoparticle nasal delivery and a neutral acute result ↗
2011 · Original animal journal research · Cortexin solution intraperitoneally or Cortexin with nanoparticles intranasally; not PPK-V
Rats with acute and chronic chemically induced seizure models; sample sizes unavailable in the abstract
Long-term pretreatment did not affect convulsions in the acute status model, while a dose-dependent antiepileptic effect was described in the chronic model. The abstract does not quantify outcomes separately by route.
- Pinealon, Cortexin and Deltaran: prenatal-stress conference findings ↗
2014 · Conference abstract · Cortexin mixture, Pinealon and Deltaran (DSIP-containing formulation); separate groups
21-day-old outbred rat offspring; seven listed treatment groups; no group sizes supplied
The abstract reports 96% survival with Deltaran and 94% with Pinealon, without denominators or an untreated-hypoxia survival rate. Learning favored Deltaran then Pinealon then Cortexin, but contradictory caspase-3 statements remain unresolved.
- Pinealon versus Cortexin after prenatal hypoxia: dissertation methods ↗
2013 · Dissertation author-abstract transcription · pinealon, cortexin
Young-rat prenatal arm and a separate 120-old-male ischemia arm; prenatal Table 2 contains two n values per group with unclear hierarchy
For gestation-day-13–20 hypoxia, third-day maze latency was 34.5±3.9 seconds with Pinealon, 58.37±3.22 with Cortexin and 121.8±19.01 with saline. Cortexin-only offspring also performed worse than intact controls. Source is an author-abstract transcription, not an authenticated full thesis.
- USING CORTEXIN TO MANAGE THE CONSEQUENCES OF PERINATAL HYPOXIC BRAIN INJURY IN INFANT RATS ↗
2016 · Original journal publication · cortexin
Infant rats with injury induced at postnatal day 7, plus intact treated controls; n absent from abstract
Cortexin transiently improved EMG spectral structure at day 10, but not amplitude; the EMG benefit was absent at day 30. Intact treated pups developed autonomic and heart-rhythm disturbances. This experiment began after birth.
- Potapov–Shustov: pharmacological correction of delayed neuropathy in rats ↗
2026 · Original preclinical journal publication · Aminoethanol and inositol derivatives, polyprenols, citicoline and Cortexin comparators
Rat study; group denominators not verified
Responses at approximately one month varied by model; an inositol derivative worsened selected neuromuscular findings in some animals.
- PPK-V versus Cortexin, Semax and Dalargin: rat peptide-profile study ↗
2020 · Original animal and analytical journal research · Commercial Cortexin, Semax and Dalargin; their combinations; experimental calf-brain hydrolysates PPK-A, B, V, G, D and E. PPK-V is cortex-derived; PPK-B is brainstem-derived.
Outbred rats; ten per treatment group and separate control groups for each endpoint. Hypoxia: three-month-old males, 250±20 g. Loaded swimming: pretrained females, 200±20 g. A pooled analysis of separate experiments, not a verified single contemporaneous head-to-head cohort.
Table 2 reports PPK-V hypoxia time 552±44 s and swimming time 289±66 s; Cortexin 201±11 s and 172±44 s; displayed controls 95±3 s and 135±6 s. Unequal doses and pooled experiments prevent a reliable potency or superiority claim.
- Cortexin modulates OPG/RANK/RANKL and TRPC1 expression in cerebral ischemia-reperfusion injury. ↗
2026 · Animal / experimental
35 male Wistar rats in five ischemia/reperfusion and comparator groups
Cortexin reduced measured oxidative stress and expression of OPG, RANK, RANKL and TRPC1 in rat brain tissue after ischemia/reperfusion.
- [The effect of neuroprotectors on the level of BDNF, tumor necrosis factor alpha and apoptosis markers, and in acute cerebrovascular accidents]. ↗
2026 · Animal / experimental
Male Wistar rats after cerebral ischemia–reperfusion
In a rat ischemia–reperfusion model, Cortexin did not significantly reduce lesion volume (32.75±4.91% versus 38.16±5.98%; p=0.198). Selected inflammatory/apoptosis markers changed, but BDNF did not.
- Neurotropic Effects of Cortexin on Models of Mental and Physical Developmental Delay. ↗
2025 · Animal / experimental
Rat developmental-delay models; separate radiolabel-distribution experiments in mice
Cortexin improved selected behavioral and histological measures in models involving maternal alcohol exposure or neonatal hypoxia–ischemia.
- [Cortexin and cortagen as correcting agents in functional and metabolic disorders in the brain in chronic ischemia]. ↗
2011 · Original journal report
Rats with experimental chronic brain ischemia
Cortagen and Cortexin accelerated recovery of disturbed behavior and reduced oxidative-stress changes.
- Histostructural changes of rat cerebral cortex during hemorrhagic stroke modeling ↗
2012 · Animal / experimental
Rat models of primary and secondary hemorrhagic stroke; brain histology
Investigators reported fewer degenerating cortical neurons with the tested preparations.
- Cortexin and combination of nitrite with cortexin decrease swelling and destruction of cerebellar neurons in hemorrhagic stroke ↗
2009 · Animal / experimental
Hemorrhagic-stroke paper; indexed citation without abstract
The title describes cerebellar injury and Cortexin with or without nitrite; no outcome is extracted from the title.
- Comparison of behavioral effects of cortexin and cerebrolysin injected into brain ventricles. ↗
2007 · Journal publication · Porcine brain-derived peptide mixture; equivalence to other hydrolysates is not assumed
Wistar rats; direct injection into brain ventricles
Kirov-associated comparison reports behavioral activation with both Cortexin and Cerebrolysin.
Cell / tissue models
- Vladonix, Endoluten and other peptides in cultured human blood cells ↗
2016 · Original journal article · Six separately assayed peptide preparations supplied by the Khavinson laboratory.
Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.
Vladonix increased cell-lysate IL-18 to a median of 66.48 vs 39.06 pg/mL with saline and lowered IL-1RA to 3,765 vs 5,228 pg/mL. The study compared six preparations in cell culture.
- Combined effect of polypeptide complexes on organotypic rat tissue cultures ↗
2023 · Original journal article · Organ-derived polypeptide preparations applied directly to rat tissue in culture.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
Three-month-old Wistar rats supplied explants. Methods report 280 liver, 300 spleen and 250 kidney explants. Donor rat count is unspecified.
At 20 ng/mL, Ventvil increased the liver explant area index by 21 ± 5% versus medium alone (17 explants). Ventvil plus Thymalin gave a 20 ± 3% increase (21 explants). Ventvil alone had no significant effect in spleen explants.
1 more studies
- [POLYPEPTIDES INFLUENCE ON TISSUE CELL CULTURES REGENERATION OF VARIOUS AGE RATS]. ↗
2015 · Original journal report
Organotypic tissue cultures from young and old rats
Calf-tissue preparations, including Ventvil, stimulated corresponding tissue-culture growth with changes in proliferation-related markers.
Read the independent stroke review; pooled Cerebrolysin/Cortexin conclusions are not Cortexin-only estimates or evidence for short peptides.
Composition, reviews & other sources (17)
- Influence of cortexin on memory and attention ↗
2004 · Review
- Cerebrolysin for acute ischaemic stroke ↗
2023 · Review
15 more sources
- Amino-acid analysis of Pineamin and three organ peptide preparations ↗
2017 · Original journal article · Free and hydrolysis-released amino acids; the measurements do not identify intact peptide sequences.
- Cortexin in a 2008 narrative review of childhood autism care ↗
2008 · Review
- Cortexin for pediatric speech-development disorders: phase II trial GP20021-P4-21 ↗
2020 · Trial registration · 10 mg intramuscular lyophilisate
- Cortexin for pediatric speech-development disorders: phase II trial GP20061-P4-02-01 ↗
2024 · Trial registration · 10 mg and 20 mg rectal suppositories
- Cortexin for pediatric speech-development disorders: phase III trial GP20061-P4-03-01 ↗
2025 · Trial registration · 20 mg rectal suppository
- Cortexin: rectal formulation application — WO2026043399A1 ↗
2026 · Patent publication · Patent-defined substance or composition
- Retinalamin plus Cortexin: optic-nerve and retinal method — RU2373904C1 ↗
2009 · Patent publication · Patent-defined substance or composition
- Retinalamin / Cortexin: local ocular delivery method — RU2195297C2 ↗
2002 · Patent publication · Patent-defined substance or composition
- Cortexin: brain-derived polypeptide complex — RU2104702C1 ↗
1998 · Patent publication · Patent-defined substance or composition
- RU2469730C2: Cortexin in a multi-stage biathlon protocol — RU2469730C2 ↗
2012 · Patent publication · Patent-defined substance or composition
- Expert Council resolution: adjunctive pharmacotherapy for hyperkinetic disorders (attention deficit hyperactivity disorder) in children and adolescents ↗
2026 · Expert-council resolution
- Эффективность применения пептидных биорегуляторов у лиц разного возраста в условиях Крайнего Севера — Effectiveness of peptide bioregulators in people of different ages under Far North conditions ↗
2003 · Dissertation record and indexed excerpts · Thymalin, Epithalamin and Cortexin tissue-derived preparations
- Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results ↗
2013 · Review
- Identification of short peptides in the composition of polypeptide complexes isolated from animal organs ↗
2020 · Analytical / composition study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
- Neuroprotective effects of peptides bioregulators in people of various age ↗
2013 · Review
Crystagen ↗
Immune product · Product / unresolved
6 human reports · 1 cell / tissue models
A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.
Studies and sources
Sequence or preparation · EDP association; formulation unverified
Related preparation · Thymic research tradition. Thymalin composition paper identifies EDP; marketed product equivalence is unverified.
Human reports
- Personified prevention of diseases under the conditions of the Far North ↗
2016 · Journal publication · Risk-assigned capsule program: Endoluten tissue extract and named synthetic peptide products; Cerluten also named in assignments
113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.
- Crystagen after radiation exposure: Medical Center clinical report ↗
2006 · Institute report / commercial reproduction · Oral Crystagen as described in the report
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
70 adults aged 38–69: 40 received adjunctive Crystagen and 30 received conventional therapy alone. Each arm included patients with low-dose radiation exposure and patients after radiation and chemotherapy.
In the low-dose radiation subgroup, CD4-positive cells were 32.1% after Crystagen plus usual care versus 29.7% after usual care alone. The table marks the change from baseline, with no reported between-group test.
4 more studies
- Oral peptide combinations in Agent Orange-exposed veterans with immune deficiency ↗
2013 · Uncontrolled human report · Vladoniks, Vezugen and Kristagen as named in the paper. Branded oral preparations.
150 veterans with immune deficiency in the Joint Vietnam–Russia Program 33. The same 150 are shown before and after treatment.
In 150 veterans, mean IgG rose from 1,202.27 to 1,445.20 mg/dL and CD4 cells from 501.96 to 569.33 cells/µL (both p<0.01). CD19 and the CD4/CD8 ratio did not change significantly.
- Oral peptide combinations for prostate symptoms in Agent Orange-exposed veterans ↗
2012 · Uncontrolled human report · Veziliut, Vezugen, Kristagen and Ventfort as named in the paper. Branded oral preparations.
150 veterans with benign prostatic hyperplasia. The same 150 are shown before and after treatment.
In 150 veterans, mean prostate symptom score (IPSS) fell from 20.94 to 8.46 (p<0.01) and urinary flow increased from 4.9 to 9.1 mL/s (p<0.001). This before-and-after comparison tested four oral products together.
- Pinealon and Crystagen in a 28-rower study ↗
2018 · Molecular and Cellular Mechanisms of Peptidergic Regulation of Brain Functions, Chapter 6.1.2, pp. 168–182
28 rowers aged 18–30, 18 men and 10 women. Active and ordinary-training groups n=14 each.
The monograph reports changes in oxidative biomarkers, alongside little change in several blood counts. It does not establish individual effects of Pinealon and Crystagen.
- Pinealon plus Crystagen in rhythmic gymnastics ↗
2012 · St. Petersburg Institute of Bioregulation and Gerontology, reproduced methodological report, Tables 2–3
20 elite female rhythmic gymnasts. Combination n=12; usual training n=8.
Morning recovery heart rate decreased from 83.8 to 74.2 beats/min in the combined arm. Heart rate during full routines and individual elements showed no significant change.
Cell / tissue models
- Vladonix, Endoluten and other peptides in cultured human blood cells ↗
2016 · Original journal article · Six separately assayed peptide preparations supplied by the Khavinson laboratory.
Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.
Vladonix increased cell-lysate IL-18 to a median of 66.48 vs 39.06 pg/mL with saline and lowered IL-1RA to 3,765 vs 5,228 pg/mL. The study compared six preparations in cell culture.
The 113-worker Gazprom program is shared multi-product evidence, not a Crystagen-only effect. Experimental spleen findings and product reports remain separate from defined EDP identity.
Composition, reviews & other sources (3)
- Identification of short peptides: optimization of target therapeutic properties of the thymus medicine ↗
2021 · Analytical / composition study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
- Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process ↗
2014 · Journal publication · Short-peptide experimental preparations; marketed-product equivalence unresolved
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
1 more sources
- Crystagen research trail: defined EDP peptide — US8057810B2 ↗
2011 · Patent publication · Patent-defined substance or composition
Sources with open questions (1)
- Pinealon + Crystagen: gymnast combination report ↗
Lead · original evidence not verified
EDL ↗
Kidney · Synthetic peptide
3 animal models · 2 cell / tissue models
Synthetic EDL reduced several measures of renal injury, including proteinuria and azotemia, and affected oxidative-stress and energy-related measures.
Studies and sources
Sequence or preparation · Glu–Asp–Leu
Related preparation · Experimental tripeptide. The kidney studies administered the defined sequence.
Animal models
- Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis ↗
2017 · Animal / experimental · Synthetic EDL tripeptide
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Rats with gentamicin-associated or ischemia/reperfusion kidney injury
Synthetic EDL reduced several measures of renal injury, including proteinuria and azotemia, and affected oxidative-stress and energy-related measures.
- Kidney polypeptide complex, EDL, AED and AEDG in aged rats ↗
2019 · Animal / experimental
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
35 rats aged 20–24 months. Five randomized groups of seven.
Two-hour urine output was 4.25 mL with the kidney complex, 4.40 with EDL and 4.78 with AED versus 3.51 in controls. AEDG lowered filtration to 406.22 versus 516.32 µL/min.
1 more studies
- Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats ↗
2015 · Animal / experimental · Injected kidney polypeptide complex, identified as Pielotax in the Russian reproduction. EDL, AED and AEDG were separate short-peptide arms.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.
Filtration rates were 433.3 with the kidney complex, 543.9 with EDL, 305.1 with AED and 469.9 with AEDG versus 240.8 µL/min with cisplatin alone. AED did not significantly improve filtration.
Cell / tissue models
- Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals ↗
2015 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Kidney explants from young and old rats
Compared kidney polypeptide complex with T-31/AED and T-35/EDL. The short peptides changed proliferation and apoptosis markers, with smaller effects than the complex.
- [Tripeptides slow down aging process in renal cell culture]. ↗
2014 · In vitro · Preparation-specific research; no equivalence inferred
Young and aged renal cell cultures, with a separate computational DNA interaction analysis.
In young and aged renal cell cultures, the short peptides AED and EDL increased proliferation and SIRT6 expression while reducing the senescence-associated markers p16, p21 and p53.
The kidney experiments used isolated EDL. Ovagen has a separate product report.
Composition, reviews & other sources (1)
- EDL: defined liver-regeneration peptide — RU2297239C1 ↗
2007 · Patent publication · Patent-defined substance or composition
Endoluten ↗
Named tissue preparation · Tissue extract
6 human reports · 1 cell / tissue models
In the dyshormonal myocardial dystrophy subgroup, estradiol was 101.3 pmol/L after Endoluten and 79.1 pmol/L after usual care. The report assessed several diagnoses separately.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Endoluten: clinical report on a tissue-derived preparation ↗
2011 · Institute report — commercial reproduction · Tissue-derived mixture / named preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
163 patients: 99 adjunctive Endoluten; 64 controls across four diagnostic subgroups.
In the dyshormonal myocardial dystrophy subgroup, estradiol was 101.3 pmol/L after Endoluten and 79.1 pmol/L after usual care. The report assessed several diagnoses separately.
- Personified prevention of diseases under the conditions of the Far North ↗
2016 · Journal publication · Risk-assigned capsule program: Endoluten tissue extract and named synthetic peptide products; Cerluten also named in assignments
113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.
4 more studies
- Suprefort with and without Cerluten and Endoluten in type 2 diabetes ↗
2013 · Conference report · company reproduction · Oral pancreas, brain and pineal polypeptide preparations added to standard therapy
918 adults aged 52–65 with type 2 diabetes: 329 standard care, 214 added Suprefort, 375 added Suprefort, Cerluten and Endoluten.
The conference report lists two-hour glucose of 9.7 mmol/L with standard care, 7.3 with added Suprefort, and 6.5 with the three-product combination.
- Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis ↗
2013 · Conference report · company reproduction · Oral vascular, brain, liver and pineal polypeptide preparations added to standard therapy
1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.
The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.
- Zhenoluten and Endoluten in women with reduced reproductive function ↗
2019 · Conference report and expanded author report · Oral ovarian and pineal polypeptide combination
276 women aged 34–38: 214 received the peptide combination and 62 received placebo.
In the 276-person comparison, anti-Müllerian hormone was 1.16 versus 0.82 ng/mL after four months. The expanded report also lists 180/214 versus 8/62 pregnancies, with limited detail on allocation and follow-up.
- Tireogen and Endoluten as adjuncts in autoimmune thyroiditis ↗
2017 · Published conference abstract with author report · Oral Tireogen, or Tireogen plus Endoluten, alongside standard treatment
218 adults aged 39–51: 89 standard treatment, 42 standard treatment plus Tireogen, 87 standard treatment plus Tireogen and Endoluten.
At four months the author table reports TSH of 7.14 with standard care, 4.09 with adjunctive Tireogen, and 3.94 mIU/L with the combination. Antibody findings are reported with inconsistencies between table and narrative.
Cell / tissue models
- Vladonix, Endoluten and other peptides in cultured human blood cells ↗
2016 · Original journal article · Six separately assayed peptide preparations supplied by the Khavinson laboratory.
Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.
Vladonix increased cell-lysate IL-18 to a median of 66.48 vs 39.06 pg/mL with saline and lowered IL-1RA to 3,765 vs 5,228 pg/mL. The study compared six preparations in cell culture.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
Composition, reviews & other sources (1)
- Endoluten plus Chonsurid: dental bone-healing method — RU2589265C2 ↗
2016 · Patent publication · Patent-defined substance or composition
Epitalon ↗
Pineal · Synthetic peptide
6 human reports · 9 animal models · 14 cell / tissue models
After 20 days, 87/270 Epimental recipients and 211/290 placebo recipients reported disturbed sleep. In the separate Regevil comparison, 110/276 and 200/244, respectively, reported fatigue.
Studies and sources
Sequence or preparation · AEDG
Related preparation · Epithalamin. AEDG detected in pineal complex after earlier sequence design.
Human reports
- Oral Epitalon for prolonged stress and Vilon during recovery from infection: two placebo comparisons ↗
2021 · Journal report of two placebo comparisons · Epimental (Epitalon, AEDG) and Regevil (Vilon, KE), tested separately as oral supplements.
Author affiliations · Academy of Postgraduate Education, Federal Research and Clinical Center, Federal Biomedical Agency, Moscow · St. Petersburg Institute of Bioregulation and Gerontology
Epimental: 560 adults aged 35–68 after prolonged occupational or emotional stress, including time-zone changes (270 active, 290 placebo). Regevil: 520 adults aged 43–76 recovering from acute respiratory, bacterial or viral illness (276 active, 244 placebo).
After 20 days, 87/270 Epimental recipients and 211/290 placebo recipients reported disturbed sleep. In the separate Regevil comparison, 110/276 and 200/244, respectively, reported fatigue.
- Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people ↗
2007 · Clinical trial / comparison · Synthetic AEDG (Epitalon)
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
40 older intervention participants: 15 Epitalon, 15 Epithalamin and 10 saline; 10 young references. Baseline survey separately included 49 older and 15 younger people.
In older adults with low baseline melatonin, Epitalon increased 03:00 plasma melatonin from 20 ± 4 to 49 ± 7 pg/mL; saline changed from 27 ± 4 to 25 ± 4. Evening melatonin also rose, while daytime concentrations did not change significantly.
4 more studies
- Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa ↗
2002 · Human comparative study · Synthetic AEDG (Epitalon)
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
162 patients (324 eyes), ages 18–72, examined; the report identifies 46 control patients (92 eyes).
The authors reported a positive clinical effect in more than 90% of Epitalon-treated retinitis-pigmentosa cases. Visual acuity rose by an average of 0.15–0.25; total visual-field borders expanded by 90–120° in 64.8% of treated cases. Conventional-care controls had visual-function improvement in 31.5% of cases.
- AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging ↗
2020 · Human study · design details unresolved · Synthetic AEDG (Epitalon)
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Middle-aged people with reduced melatonin-producing function; no cohort size given in the indexed abstract.
The human study reports a 1.7-fold increase in urinary 6-sulfatoxymelatonin, 1.9–2.1-fold normalization of Clock/Csnk1e overexpression and a twofold increase in Cry2 expression.
- AEDG Peptide Regulates the Expression of Circadian Genes Clock, Cry2, Csnk1e in Human Immune Cells ↗
2021 · Clinical trial / comparison · Synthetic AEDG (Epitalon)
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
75 night-shift women ages 40–59: 35 normal-melatonin references; 40 with reduced function randomly divided between AEDG and placebo.
After 20 days of sublingual AEDG, Cry2 expression doubled from baseline and was 1.2-fold higher than placebo. Csnk1e expression fell 2.1-fold from baseline and was 1.8-fold lower than placebo; all reported comparisons p<0.05.
- Epitalon and Cortexin after acute systemic cold injury ↗
2009 · Candidate dissertation author abstract, Tables 1–3
Hospitalized cold-injury patients. Three adjunct arms had 25 patients each. The severity-specific outcome tables use smaller subgroups.
In the severe-injury table, day-five neuron-specific enolase was 23.2 ng/mL with both agents and 58.9 ng/mL with standard care. No formal interaction analysis was reported.
Animal models
- Investigation of antihypoxic properties of short peptides ↗
2008 · Journal publication · Synthetic peptide / defined-sequence research
Experimental hypobaric/prenatal hypoxia models
The comparative report describes antihypoxic activity, with the largest effect for Pinealon in the tested model.
- Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats ↗
2015 · Animal / experimental · Injected kidney polypeptide complex, identified as Pielotax in the Russian reproduction. EDL, AED and AEDG were separate short-peptide arms.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.
Filtration rates were 433.3 with the kidney complex, 543.9 with EDL, 305.1 with AED and 469.9 with AEDG versus 240.8 µL/min with cisplatin alone. AED did not significantly improve filtration.
7 more studies
- Kidney polypeptide complex, EDL, AED and AEDG in aged rats ↗
2019 · Animal / experimental
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
35 rats aged 20–24 months. Five randomized groups of seven.
Two-hour urine output was 4.25 mL with the kidney complex, 4.40 with EDL and 4.78 with AED versus 3.51 in controls. AEDG lowered filtration to 406.22 versus 516.32 µL/min.
- Age and baseline anxiety in Lysenko’s peptide stress models ↗
2006 · Doctoral dissertation, 244 pp., introduction and conclusions
Rats grouped by age and baseline anxiety; series-specific denominators remain unverified.
The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.
- Pinealon after maternal hypoxia: offspring and adult-rat findings ↗
2008 · Original journal publication · Pinealon in maternal arm; separate adult-male Vilon, Vesugen, Pinealon and Epitalon arms
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Pregnant rats exposed to hypoxia on gestation day 10; separate adult-male experiment, n=10/group; offspring open-field strata n=6, 11, 9 and 12
Pinealon-treated hypoxic dams had 14±2 offspring versus 9±3 with saline (p<0.05). Offspring activity and neuronal responses changed. Adult-rat Table 1 reports 10% mortality with both Pinealon and saline, conflicting with the narrative claim of higher Pinealon mortality.
- Epitalon in pregnant rats: altered brain development and behavior ↗
2007 · Original journal publication · Synthetic Epitalon (Ala-Glu-Asp-Gly), distinct from Epithalamin tissue extract
44 pups from five treated dams; control offspring n=16 from three intact dams and n=14 from two saline-treated dams. Day-1 and day-40 tissue groups n=36 and n=38 overall.
At day 40, exposed offspring weighed 73.6±2.6 g versus 83.4±4.9 g in pooled controls. Cortical measurements increased, while behavior at day 30 suggested less exploration and more anxiety. Larger brain measurements were not demonstrated benefits.
- Melatonin and pineal gland peptides are able to correct the impairment of reproductive cycles in rats ↗
2012 · Original journal publication · Epitalon (Ala-Glu-Asp-Gly), Epithalamin pineal extract and melatonin in separate comparisons
Nonpregnant female rats in a xenobiotic-induced reproductive-aging model; n absent from abstract
Epithalamin reportedly restored hypothalamic norepinephrine rhythms, while Epitalon had a stronger dopamine-rhythm effect in another hypothalamic region. The experiment used 1,2-dimethylhydrazine, not a pregnancy model or a methionine-only intervention.
- LCP2 mediates SUV39H1-driven cellular senescence-related chemoresistance in natural killer/T-cell lymphoma. ↗
2026 · Animal / experimental
Drug-resistant lymphoma cell models, patient plasma biomarker analysis and an in-vivo experimental model
The authors report that targeting a senescence-related pathway with Epitalon and Chaetocin partly removed therapy-induced senescent cells and improved chemotherapy response in experimental models. Patient plasma was used for biomarker analysis, not to test Epitalon treatment.
- [Effects of Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly peptides on hormonal activity and thyroid morphology in hypophysectomized mature and old birds]. ↗
2011 · Original journal report
Mature and old hypophysectomized birds
KEDG and AEDG improved thyroid-related hormonal and morphological measures after experimental pituitary removal.
Cell / tissue models
- Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro ↗
2016 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Aging skin-fibroblast cultures; KE, KED, AED and AEDG
The peptides altered proliferation, remodeling and aging-associated protein markers. AED and AEDG also reduced caspase-dependent apoptosis in this model.
- Biological activity of regulatory peptides in model experiments in vitro ↗
2008 · Journal publication · Synthetic peptide / defined-sequence research
Lipoprotein, erythrocyte and neuronal model experiments
The peptides did not behave as direct antioxidants. Effects on lipid peroxidation, membrane stability and neuronal survival differed by peptide.
12 more studies
- Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum ↗
2003 · Journal publication · Defined synthetic peptides
Human-serum enzyme assay and rat-brain membrane receptor-binding assay.
Livagen and Epitalon inhibited enkephalin breakdown in human serum, with IC50 values of 20 and 500 µM respectively. Neither bound the tested µ- or δ-opioid receptors.
- Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen ↗
2001 · Journal publication · Defined synthetic peptides
Cultured hepatocytes from rats aged 1–24 months.
Livagen increased protein synthesis in cultured rat liver cells, most strongly in cells from old animals. Epitalon did not change protein-synthesis intensity in this experiment.
- Effects of short peptides on lymphocyte chromatin in senile subjects ↗
2004 · Journal publication · Defined synthetic peptides
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Leukocytes sampled from people aged 75–88 years and exposed to peptides in culture.
Five short peptides increased ribosomal-gene activity and altered condensed chromatin in sampled leukocytes. Epitalon, Livagen and Prostamax changed chromosome-1 pericentromeric chromatin; Epitalon and Livagen also changed chromosome 9.
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line ↗
2022 · Journal publication · Defined peptides and Thymalin peptide complex tested separately
THP-1 leukemia-derived monocytes, differentiated macrophages and an activated HUVEC endothelial adhesion model.
Five preparations reduced LPS-induced TNF and IL-6 expression in differentiated THP-1 cells and reduced adhesion to activated endothelial cells. Chonluten also reduced monocyte TNF release; the full text notes an apoptotic cell fraction with Chonluten.
- Vladonix, Endoluten and other peptides in cultured human blood cells ↗
2016 · Original journal article · Six separately assayed peptide preparations supplied by the Khavinson laboratory.
Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.
Vladonix increased cell-lysate IL-18 to a median of 66.48 vs 39.06 pg/mL with saline and lowered IL-1RA to 3,765 vs 5,228 pg/mL. The study compared six preparations in cell culture.
- Epitalon did not change melatonin release from perifused rat pineal glands ↗
2003 · In vitro
Pineal glands from 9-week-old and 27-month-old male Wistar rats.
AEDG at 1–100 µM did not significantly change melatonin secretion in either age group. It also did not change the response to isoproterenol.
- Epitalon and Vilon in rat pinealocyte culture ↗
2012 · In vitro
Cultured rat pinealocytes.
The abstract reports increased AANAT and phosphorylated CREB and higher culture-medium melatonin with Epitalon. It describes stronger marker expression when norepinephrine was added with the peptides.
- Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. ↗
2025 · In vitro
Normal human epithelial/fibroblast cells and 21NT/BT474 breast-cancer cell lines
Epitalon was associated with telomere extension through telomerase-related changes in normal cells and alternative lengthening of telomeres (ALT) in cancer cell lines.
- The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy. ↗
2025 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
High-glucose-exposed ARPE-19 retinal pigment epithelial cells
Epitalon improved scratch-wound closure and reduced oxidative-stress, epithelial–mesenchymal-transition and fibrosis-related measures in a retinal cell model.
- Effects of short peptides on thymocyte blast transformation and signal transduction along the sphingomyelin pathway. ↗
2002 · Original journal report
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Mouse thymocytes
Vilon stimulated thymocyte proliferation most strongly; Epitalon was less active and Cortagen showed no such effect.
- Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. ↗
2011 · Original journal report · Defined synthetic peptides tested in cell uptake or DNA-binding assays
HeLa cells and nucleic-acid fluorescence assays
Fluorescent Epitalon, Pinealon and Testagen entered HeLa cells and nuclei. Separate fluorescence assays found sequence-dependent DNA binding, including for Bronchogen.
- Effect of short peptides on neuronal differentiation of stem cells ↗
2019 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Human periodontal-ligament stem-cell cultures
Examined AED, KED, KE, AEDG and their mixture. Increased neuronal-marker expression was reported for KED and the mixture.
Epithalamin gerontology and cardiovascular cohorts belong to the extract, not synthetic AEDG. Direct AEDG human reports cover melatonin, circadian markers and retinal disease; these do not establish lifespan extension. Related circadian reports may share participants.
Composition, reviews & other sources (11)
- Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland ↗
2017 · Analytical / composition study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
- Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties ↗
2025 · Review
9 more sources
- 2026 European publication: modified GHK, Epitalon, Semax, Selank and Cortagen analogues — EP4758157A1 ↗
2026 · Patent publication · Patent-defined substance or composition
- Peptide oral-delivery application: capsule within capsule — EP4757825A1 ↗
2026 · Patent publication · Patent-defined substance or composition
- Epitalon: AEDG molecular patent — US6727227B1 ↗
2004 · Patent publication · Patent-defined substance or composition
- Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence. ↗
2026 · Review
- Pharmaceutical single dosage form for oral delivery of peptides — EP4226918A1 ↗
2023 · Patent report
- Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. ↗
2025 · Publisher correction; no new experiment
- Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression ↗
2013 · Review
- Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease ↗
2022 · Review
- Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters ↗
2023 · Study design unresolved
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
Epithalamin ↗
Pineal · Tissue extract
7 human reports · 5 animal models
The abstract describes a randomized comparison and reports favorable long-term cardiovascular and mortality outcomes with the pineal extract.
Studies and sources
Sequence or preparation · Mixture
Related preparation · Pineal tissue preparation. Contains multiple components; not interchangeable with AEDG.
Human reports
- Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging ↗
2006 · Randomized trial
Older patients with coronary disease and accelerated cardiovascular aging; 12-year follow-up
The abstract describes a randomized comparison and reports favorable long-term cardiovascular and mortality outcomes with the pineal extract.
- Peptides of pineal gland and thymus prolong human life ↗
2003 · Human comparative study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
266 older people followed for 6–8 years
The investigators reported differences in illness and mortality across extract-treatment groups and controls. This is research on Thymalin and Epithalamin, including their combination.
5 more studies
- Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people ↗
2004 · Uncontrolled human report
Older adults; plasma melatonin before and after treatment
Reported changes in nighttime melatonin that differed according to baseline pineal activity.
- Epithalamin and 15-year follow-up in older adults with coronary disease ↗
2011 · Human comparative study
79 older patients with coronary disease. Thirty-nine received adjunctive Epithalamin and 40 received standard care alone.
At 15 years, 26/39 patients in the Epithalamin group and 16/40 in the standard-care group were alive. This small historical comparison followed patients with coronary disease.
- Four intranasal peptide arms at simulated 4,500 m ↗
2014 · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12
Men aged 20–25 with asthenic or immune-status features. Four active arms of 6–8 each and 11 saline controls.
Thymogen was associated with lower lactate during the chamber protocol. Cortexin showed longer complex reaction latency alongside other physiological changes. The endpoints were heterogeneous.
- Cheprasov’s Medilab peptide comparisons in aerospace stress ↗
1997 · Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods
116 men across three stress comparisons (30, 70 and 16), plus an eight-cosmonaut comparison within the reported dissertation program of 328.
The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.
- Thymalin, Epithalamin and Vilon after complicated appendicitis ↗
2008 · Original clinical journal article
Author affiliations · Chita Medical Institute
84 adults aged 18–42: 12 with uncomplicated appendicitis and 72 with postoperative wound infection. Of the 72, 62 received a peptide adjunct. Thirty healthy volunteers were a laboratory reference group.
Mean hospital stay was 24.2 days with standard care and 18.0–19.0 days in the four adjunct groups. TNF-α fell most in the Vilon cytokine subset. IL-8 increased in every measured group.
Animal models
- Thymogen and four peptide preparations in hypoxia, heat and cold ↗
2018 · Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11
Outbred male mice in the single-dose hypoxia screen; male rats (180–210 g) in the repeated-dose hypoxia table. Separate temperature experiments.
In the three-day rat comparison, Thymogen at 0.1 mg/kg gave 28.6±11.8 min versus 2.2±0.1 with saline. All 16 arms and their reported values match the 2014 monograph. Thymogen had no significant benefit on the air-cooling endpoint.
- Age and baseline anxiety in Lysenko’s peptide stress models ↗
2006 · Doctoral dissertation, 244 pp., introduction and conclusions
Rats grouped by age and baseline anxiety; series-specific denominators remain unverified.
The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.
3 more studies
- Epithalamin under exercise and restricted movement in younger and older rats ↗
2004 · Dissertation · Epithalamin pineal extract; distinct from Epitalon, Pinealon and Pineamin.
Younger and older rats; baseline, exhaustive physical loading and restricted-movement series
The author reports stronger Epithalamin-associated stress-marker responses during exhaustive exercise in younger animals, and during restricted movement in older animals.
- Melatonin and pineal gland peptides are able to correct the impairment of reproductive cycles in rats ↗
2012 · Original journal publication · Epitalon (Ala-Glu-Asp-Gly), Epithalamin pineal extract and melatonin in separate comparisons
Nonpregnant female rats in a xenobiotic-induced reproductive-aging model; n absent from abstract
Epithalamin reportedly restored hypothalamic norepinephrine rhythms, while Epitalon had a stronger dopamine-rhythm effect in another hypothalamic region. The experiment used 1,2-dimethylhydrazine, not a pregnancy model or a methionine-only intervention.
- Epithalamin and melatonin in rat brain during acute hypoxia ↗
2012 · Animal / experimental
97 young outbred male rats in the overall study. Both tables say n = 7, and the methods describe pooling tissue from two animals per suspension.
Under simulated 12,000 m hypoxia, hippocampal malondialdehyde was 27.3 µmol/g with Epithalamin, 35.6 with melatonin and 52.9 with hypoxia alone. Epithalamin reduced hippocampal protein oxidation but did not reduce cortical protein oxidation in the same pattern.
Some aging publications may follow the same participants.
Composition, reviews & other sources (5)
- Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland ↗
2017 · Analytical / composition study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
- Pineal extracts: manufacturing and composition patent — RU2163129C1 ↗
2001 · Patent publication · Patent-defined substance or composition
3 more sources
- Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence. ↗
2026 · Review
- Эффективность применения пептидных биорегуляторов у лиц разного возраста в условиях Крайнего Севера — Effectiveness of peptide bioregulators in people of different ages under Far North conditions ↗
2003 · Dissertation record and indexed excerpts · Thymalin, Epithalamin and Cortexin tissue-derived preparations
- Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results ↗
2013 · Review
Glandokort ↗
Named tissue preparation · Tissue extract
1 human reports
In the adrenal-insufficiency table, plasma aldosterone was 38.5 versus 26.2 pg/mL after adjunctive Glandokort and conventional care, respectively. The subgroup sizes are unclear.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Glandokort: clinical report on a tissue-derived preparation ↗
2011 · Institute report — commercial reproduction · Tissue-derived mixture / named preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
36 patients described; 26 controls separately stated. Enrollment denominator unresolved.
In the adrenal-insufficiency table, plasma aldosterone was 38.5 versus 26.2 pg/mL after adjunctive Glandokort and conventional care, respectively. The subgroup sizes are unclear.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
Gotratix ↗
Named tissue preparation · Tissue extract
1 human reports
At two months, both grip measures and standing long jump improved from baseline in the Gotratix group. Step-test and flexibility changes were nonsignificant.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Gotratix With Regular Training: 2011 Grip and Jump Study ↗
2011 · Institute report — commercial reproduction · Tissue-derived mixture / named preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
37 former athletes aged 40–65 in the signed scan, 20 assigned to Gotratix plus training and 17 to training alone. The analyzed denominator is unclear.
At two months, both grip measures and standing long jump improved from baseline in the Gotratix group. Step-test and flexibility changes were nonsignificant.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
KED ↗
Vessels / brain · Synthetic peptide
2 animal models · 3 cell / tissue models
Peptides showed no significant LTP restoration. Pooled total spine density differed with EDR but not KED; effects varied by sex and spine subtype.
Studies and sources
Sequence or preparation · Lys–Glu–Asp
Related preparation · Vascular polypeptide research. The 2020 composition paper detected KED in a vascular extract.
Animal models
- Neuroprotective Effects of Tripeptides—Epigenetic Regulators in Mouse Model of Alzheimer’s Disease ↗
2021 · Animal / experimental
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
5xFAD mouse model and neuronal research
Peptides showed no significant LTP restoration. Pooled total spine density differed with EDR but not KED; effects varied by sex and spine subtype.
- Pancragen in irradiated older rats: pancreatic proliferation markers ↗
2008 · Dissertation author abstract · Pancragen and separate Lys–Glu–Asp (T-38) comparator in irradiated aged rats
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
50 male Wistar rats, five groups of ten: young intact, aged intact, aged irradiated, aged irradiated plus T-38, and aged irradiated plus Pancragen.
Pancreatic PCNA-positive density was 8,176 per mm² with Pancragen and 6,524 per mm² with irradiation alone. T-38 was tested in a separate arm and had a density of 7,812 per mm².
Cell / tissue models
- Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro ↗
2016 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Aging skin-fibroblast cultures; KE, KED, AED and AEDG
The peptides altered proliferation, remodeling and aging-associated protein markers. AED and AEDG also reduced caspase-dependent apoptosis in this model.
- Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides ↗
2020 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Human embryonic bone-marrow MSC line FetMSCs, aged in culture
AED, KED and KE changed expression of selected aging-related genes. Effects depended on peptide and culture-aging model; KED affected TNKS2 in opposite directions across models.
1 more studies
- Effect of short peptides on neuronal differentiation of stem cells ↗
2019 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Human periodontal-ligament stem-cell cultures
Examined AED, KED, KE, AEDG and their mixture. Increased neuronal-marker expression was reported for KED and the mixture.
The mouse study tested the defined tripeptide. Vesugen and Slavinorm clinical publications identify their own preparations.
Composition, reviews & other sources (5)
- Identification of short peptides in the composition of polypeptide complexes isolated from animal organs ↗
2020 · Analytical / composition study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
- KED / Vesugen: defined peptide and microcirculation claims — US7851449B2 ↗
2010 · Patent publication · Patent-defined substance or composition
3 more sources
- Peptidergic regulation of age-related alterations in the cardiovascular system ↗
2026 · Journal publication
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
- Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation ↗
2023 · Review
- Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease ↗
2022 · Review
Libidon ↗
Named tissue preparation · Tissue extract
1 human reports
In the reproduced Libidon report, mean urinary flow at 30 days was 23.5 vs 19.8 mL/s in chronic prostatitis and 17.5 vs 14.2 mL/s in benign prostatic hyperplasia with adjunctive Libidon versus usual care.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Libidon: clinical report reproduced in the Russian institute-report collection (2011) ↗
2011 · Institute report — commercial reproduction · Prostate-derived peptide mixture
48 treated men aged 38–65 (28 chronic prostatitis, 20 benign prostatic hyperplasia); 22 controls described separately; full denominator reconciliation pending
In the reproduced Libidon report, mean urinary flow at 30 days was 23.5 vs 19.8 mL/s in chronic prostatitis and 17.5 vs 14.2 mL/s in benign prostatic hyperplasia with adjunctive Libidon versus usual care.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
Livagen ↗
Liver · Synthetic peptide
1 animal models · 5 cell / tissue models
Oral Livagen changed digestive-enzyme activity in opposite directions by age: decreases in young rats and increases in old rats.
Studies and sources
Sequence or preparation · KEDA
Related preparation · Ventvil. Russian review distinguishes defined KEDA from liver extract.
Animal models
- [Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages]. ↗
2005 · Original journal report
Young and old rats; companion digestive-enzyme assays
Oral Livagen changed digestive-enzyme activity in opposite directions by age: decreases in young rats and increases in old rats.
Cell / tissue models
- Effects of Livagen peptide on chromatin activation in lymphocytes from old people. ↗
2002 · Original journal report
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Cultured lymphocytes from older donors
Livagen altered chromatin organization and ribosomal-gene activity in donor-derived lymphocytes.
- Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum ↗
2003 · Journal publication · Defined synthetic peptides
Human-serum enzyme assay and rat-brain membrane receptor-binding assay.
Livagen and Epitalon inhibited enkephalin breakdown in human serum, with IC50 values of 20 and 500 µM respectively. Neither bound the tested µ- or δ-opioid receptors.
3 more studies
- Functional morphology of an organotypic liver culture exposed to the peptide livagen ↗
2002 · Journal publication · Defined synthetic peptide
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Organotypic liver culture; sample size and species not supplied in the indexed abstract.
Livagen supported liver-cell structural integrity and regeneration-related morphology in an organotypic culture. The abstract supplies no numerical effect size.
- Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen ↗
2001 · Journal publication · Defined synthetic peptides
Cultured hepatocytes from rats aged 1–24 months.
Livagen increased protein synthesis in cultured rat liver cells, most strongly in cells from old animals. Epitalon did not change protein-synthesis intensity in this experiment.
- Effects of short peptides on lymphocyte chromatin in senile subjects ↗
2004 · Journal publication · Defined synthetic peptides
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Leukocytes sampled from people aged 75–88 years and exposed to peptides in culture.
Five short peptides increased ribosomal-gene activity and altered condensed chromatin in sampled leukocytes. Epitalon, Livagen and Prostamax changed chromosome-1 pericentromeric chromatin; Epitalon and Livagen also changed chromosome 9.
Chromatin findings concern cultured donor lymphocytes; enzyme findings concern rats. Neither establishes human liver benefit.
Composition, reviews & other sources (3)
- The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology ↗
2020 · Review
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
- Livagen: KEDA molecular and hepatocyte-use claims — US7101854B2 ↗
2006 · Patent publication · Patent-defined substance or composition
Sources with open questions (1)
- Livagen hepatitis patent examples ↗
Lead · original evidence not verified
Nephropept ↗
Kidney · Tissue extract
1 cell / tissue models
At 20 ng/mL, Ventvil increased the liver explant area index by 21 ± 5% versus medium alone (17 explants). Ventvil plus Thymalin gave a 20 ± 3% increase (21 explants). Ventvil alone had no significant effect in spleen explants.
Studies and sources
Sequence or preparation · Polypeptide mixture
Related preparation · Kidney-derived complex. No sequence-specific composition established by the linked study.
Cell / tissue models
- Combined effect of polypeptide complexes on organotypic rat tissue cultures ↗
2023 · Original journal article · Organ-derived polypeptide preparations applied directly to rat tissue in culture.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
Three-month-old Wistar rats supplied explants. Methods report 280 liver, 300 spleen and 250 kidney explants. Donor rat count is unspecified.
At 20 ng/mL, Ventvil increased the liver explant area index by 21 ± 5% versus medium alone (17 explants). Ventvil plus Thymalin gave a 20 ± 3% increase (21 explants). Ventvil alone had no significant effect in spleen explants.
The Phase II registry describes the planned study. Outcomes are unavailable.
Composition, reviews & other sources (1)
- Nephropept NPR-11-2022: Phase II trial registration ↗
2023 · Trial registration — results not reported · Investigational Nephropept preparation in a registered Phase II protocol; this registry record is not a report of completed treatment outcomes.
Normophthal ↗
Retina · Synthetic peptide
2 human reports
After 40 days, uncorrected visual acuity in the 45–59-year subgroup was 0.62 with adjunctive Normophthal and 0.60 with Retinalamin alone. The author reports no significant additional clinical effect in the oldest subgroup.
Studies and sources
Sequence or preparation · Identity retained at catalogue level
Related preparation · Retinalamin is a distinct extract. Shared retinal theme only; direct molecular derivation not established here.
Human reports
- Normophthal added to Retinalamin for early age-related macular degeneration ↗
2013 · Dissertation author abstract · Oral Normophthal after injected Retinalamin versus injected Retinalamin alone
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
120 patients with early age-related macular degeneration, 213 eyes: 67 in the combination group and 53 in the Retinalamin group.
After 40 days, uncorrected visual acuity in the 45–59-year subgroup was 0.62 with adjunctive Normophthal and 0.60 with Retinalamin alone. The author reports no significant additional clinical effect in the oldest subgroup.
- Peptide regulators in age-related macular degeneration: Normophthal comparison ↗
2013 · Original clinical journal publication · Named Normophthal preparation; isolated peptide identity not established
45 patients: 25 adjunctive Normophthal, 20 conventional-care comparison
Favorable visual-function narrative accompanies tables labeled p≥0.05 versus baseline.
The 2013 dissertation compared Retinalamin followed by Normophthal with Retinalamin alone. The 45-patient journal report used a conventional-care comparison.
Composition, reviews & other sources (2)
- Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression ↗
2013 · Review
- Normophthal / Lys-Glu: ocular angiogenesis use — RU2177801C1 ↗
2002 · Patent publication · Patent-defined substance or composition
Ovagen ↗
Liver product / renal sequence research · Product / unresolved
1 human reports
In the chronic-hepatitis table, bilirubin was 28.4 µmol/L before treatment, 21.5 after adjunctive Ovagen and 26.4 after usual care. ALT and IgM were marked lower than baseline in both groups.
Studies and sources
Sequence or preparation · EDL association; formulation unverified
Related preparation · Relationship to Ventvil unresolved. The renal culture paper studies T-35/EDL; linking it to a marketed Ovagen product requires characterization.
Human reports
- Oral Ovagen in chronic hepatitis and after chemotherapy ↗
2011 · Institute report — commercial reproduction · Named oral Ovagen product. The report lists glutamic acid, aspartic acid and leucine, with no sequence or batch characterization.
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
40 receiving adjunctive Ovagen (20 with persistent chronic hepatitis, 20 after chemotherapy) and 34 usual-care controls. The treated series was aged 38–67.
In the chronic-hepatitis table, bilirubin was 28.4 µmol/L before treatment, 21.5 after adjunctive Ovagen and 26.4 after usual care. ALT and IgM were marked lower than baseline in both groups.
The Russian and English institute reports describe the same 40 treated and 34 comparison participants. The synthetic EDL studies describe a different preparation.
Composition, reviews & other sources (1)
- Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals ↗
2015 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Sources with open questions (2)
- Ovagen: conflicting clinical cohort claims ↗
Lead · original evidence not verified
- Laboratory-code dictionary acquisition ↗
Lead · original evidence not verified
Pancragen ↗
Pancreas · Synthetic peptide
2 human reports · 5 animal models · 3 cell / tissue models
In the older adults with type 2 diabetes, the paper reports lower fasting and challenge glucose, insulin and insulin resistance with Pancragen. The untreated diabetes comparison showed no reported change in carbohydrate markers.
Studies and sources
Sequence or preparation · KEDW; terminal form must be checked
Related preparation · Pancreatic polypeptide complex. KEDW reported in composition research; individual experiments may specify an amidated form.
Human reports
- Prospects of using pancragen for correction of metabolic disorders in elderly people ↗
2011 · Journal publication · Synthetic peptide / defined-sequence research
30 healthy older people and 33 older people with type-2 diabetes
In the older adults with type 2 diabetes, the paper reports lower fasting and challenge glucose, insulin and insulin resistance with Pancragen. The untreated diabetes comparison showed no reported change in carbohydrate markers.
- Pancragen Forte: four weeks in 12 older adults with impaired glucose tolerance ↗
2013 · Original journal report · Pancragen Forte (Pankragen-forte in the abstract)
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
12 older adults with impaired glucose tolerance received treatment. The screening sample included 150 people across three age groups, of whom 69 were 60 or older.
After four weeks of Pancragen Forte at 500 µg twice daily, the authors reported lower glucose during a tolerance test in half of the 12 treated adults. The abstract leaves the size of the change and the response threshold unspecified.
Animal models
- Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys ↗
2014 · Journal publication · Synthetic peptide / defined-sequence research
Old female rhesus monkeys; younger comparison animals
Reports glucose-clearance and insulin/C-peptide changes after treatment, with some changes persisting after withdrawal.
- Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys ↗
2015 · Journal publication · Synthetic peptide / defined-sequence research
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Nine old rhesus monkeys: five Pancragen, four glimepiride
Compared glucose and endocrine responses with glimepiride; the groups showed different insulin/C-peptide patterns.
3 more studies
- Pancragen in diabetic rats: blood glucose and mesenteric capillary outcomes ↗
2007 · Original journal report · Oral and intramuscular Pancragen (Lys–Glu–Asp–Trp–NH₂)
Wistar rats with streptozotocin-induced diabetes. The abstract leaves arm sizes, doses and observation time unspecified.
The authors reported lower blood glucose during oral treatment and normalization of endothelial adhesion measures after intramuscular treatment. Capillary permeability was unchanged with intramuscular treatment.
- Pancragen in irradiated older rats: pancreatic proliferation markers ↗
2008 · Dissertation author abstract · Pancragen and separate Lys–Glu–Asp (T-38) comparator in irradiated aged rats
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
50 male Wistar rats, five groups of ten: young intact, aged intact, aged irradiated, aged irradiated plus T-38, and aged irradiated plus Pancragen.
Pancreatic PCNA-positive density was 8,176 per mm² with Pancragen and 6,524 per mm² with irradiation alone. T-38 was tested in a separate arm and had a density of 7,812 per mm².
- Pancragen and pancreatic cell markers in streptozotocin-treated rats ↗
2007 · Original journal abstract with dissertation author abstract · Synthetic amidated Lys–Glu–Asp–Trp (KEDW-NH₂)
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
28 male Wistar rats, four groups of seven: intact, streptozotocin only, streptozotocin with intramuscular Pancragen, and streptozotocin with oral Pancragen.
Insulin-positive pancreatic cell area was 6.43% with injected Pancragen, 5.53% with oral Pancragen and 2.42% with streptozotocin alone. Insulin staining intensity was similar across groups.
Cell / tissue models
- Effects of pancragen on the differentiation of pancreatic cells during their ageing ↗
2013 · Journal publication · Synthetic peptide / defined-sequence research
Pancreatic cell cultures
Investigates differentiation-marker expression in aging cultures. Molecular changes are a mechanistic hypothesis, not demonstrated organ restoration.
- The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats ↗
2006 · Journal publication · Synthetic peptide / defined-sequence research
Heart, lung, prostate and pancreatic explants from young and old rats
Reports tissue-specific growth responses to the corresponding synthetic peptides in organotypic cultures.
1 more studies
- Peptides tissue-specifically stimulate cell differentiation during their aging ↗
2012 · Journal publication · Defined synthetic peptides
Human embryonic pancreatic and bronchial cell cultures, plus human prostatic fibroblasts, compared at different passage ages.
Pancragen increased differentiation-marker expression in pancreatic cells, Bronchogen in bronchial cells, and Vesugen in prostatic fibroblasts. Responses were more pronounced in aged cultures.
The primate comparison is not a human trial. Healthy comparison subjects are not automatically randomized treatment controls.
Composition, reviews & other sources (3)
- Identification of short peptides in the composition of polypeptide complexes isolated from animal organs ↗
2020 · Analytical / composition study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
- Pancragen trail: terminally amidated KEDW — RU2242241C1 ↗
2004 · Patent publication · Patent-defined substance or composition
Sources with open questions (1)
- Pancragen: additional institute cohort claim ↗
Lead · original evidence not verified
PCC ↗
Cartilage · Tissue extract
Studies and sources
Sequence or preparation · Mixture
Related preparation · Cartilage polypeptide complex. AED detection does not make the mixture Cartalax.
Review-reported Phase II program; original clinical trial not recovered.
Composition, reviews & other sources (3)
- Peptide Regulation of Chondrogenic Stem Cell Differentiation ↗
2023 · Review
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
- Identification of short peptides in the composition of polypeptide complexes isolated from animal organs ↗
2020 · Analytical / composition study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
1 more sources
- PCC: corrected cartilage-complex publication — RU2302872C9 ↗
2008 · Patent publication · Patent-defined substance or composition
Sources with open questions (1)
- PCC osteoarthritis Phase II program — original trial recovery target ↗
Trial not recovered · link is to the citing review
Pielotax ↗
Named tissue preparation · Tissue extract
1 human reports · 1 animal models
After 30 days, blood urate was 0.44 versus 0.56 mmol/L in men and 0.37 versus 0.48 mmol/L in women, comparing adjunctive Pielotax with conventional treatment.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Pielotax: clinical report on a tissue-derived preparation ↗
2011 · Institute report — commercial reproduction · Tissue-derived mixture / named preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Gouty nephropathy: 27 treated, 15 controls.
After 30 days, blood urate was 0.44 versus 0.56 mmol/L in men and 0.37 versus 0.48 mmol/L in women, comparing adjunctive Pielotax with conventional treatment.
Animal models
- Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats ↗
2015 · Animal / experimental · Injected kidney polypeptide complex, identified as Pielotax in the Russian reproduction. EDL, AED and AEDG were separate short-peptide arms.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.
Filtration rates were 433.3 with the kidney complex, 543.9 with EDL, 305.1 with AED and 469.9 with AEDG versus 240.8 µL/min with cisplatin alone. AED did not significantly improve filtration.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
Pinealon ↗
Brain / occupational research · Synthetic peptide
9 human reports · 11 animal models · 6 cell / tissue models
Reports biological-age and adaptation indicators after short-term Pinealon use.
Studies and sources
Sequence or preparation · EDR
Related preparation · Brain polypeptide complex; Cortexin is a distinct preparation. EDR detected in brain complex; not proof of equivalence to a clinical Cortexin product.
Human reports
- Analysis of some parameters of biological age and adaptation possibilities of workers of locomotive brigades ↗
2012 · Journal publication · Synthetic peptide / defined-sequence research
Locomotive-brigade workers
Reports biological-age and adaptation indicators after short-term Pinealon use.
- The peptide correction of neurotic disorders among professional truck-drivers ↗
2012 · Human comparative study · Pinealon and Vezugen peptide bioregulators, including combined use. The abstract does not specify the dosage form.
150 male lorry drivers and 150 male metal craftsmen in the occupational comparison
The abstract describes occupational psychoemotional differences and reports changes with peptide bioregulators, including combined Pinealon and Vezugen.
7 more studies
- Personified prevention of diseases under the conditions of the Far North ↗
2016 · Journal publication · Risk-assigned capsule program: Endoluten tissue extract and named synthetic peptide products; Cerluten also named in assignments
113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.
- Oral Pinealon and Vesugen in older men: four-arm randomized comparison ↗
2010 · Dissertation author abstract · Branded oral Pinealon (EDR) and Vesugen (KED) capsules. The report does not specify the peptide mass per capsule.
170 men aged 60–74. Pinealon 43, Vesugen 45, both 42, Decamevit multivitamin control 40.
After 30 days, working-memory scores were 17.4 with Pinealon, 17.8 with Vesugen and 17.5 with both, versus 12.4 with multivitamins. The combination had the largest change on the composite severity index. At five-month follow-up, the figure marks a baseline difference only for that index in the combination arm.
- Pinealon and balance in artistic gymnasts ↗
2013 · XXII Pavlov Physiological Society Congress, Volgograd, printed p. 362
16 artistic gymnasts aged 18–22 and 20 male students as controls.
Gymnasts spent 55% of the balance test with their center of mass in the center of the target after Pinealon. The abstract reports improvement over earlier readings.
- Pinealon in female judo athletes ↗
2012 · Original journal text, Tables 2–3
18 female judo athletes aged 16–22; blood measures in 10.
Post-load balance score increased from 57.95±6.28% to 77.24±0.96%. The separate blood subset had lower ESR.
- Pinealon and Crystagen in a 28-rower study ↗
2018 · Molecular and Cellular Mechanisms of Peptidergic Regulation of Brain Functions, Chapter 6.1.2, pp. 168–182
28 rowers aged 18–30, 18 men and 10 women. Active and ordinary-training groups n=14 each.
The monograph reports changes in oxidative biomarkers, alongside little change in several blood counts. It does not establish individual effects of Pinealon and Crystagen.
- Pinealon plus Crystagen in rhythmic gymnastics ↗
2012 · St. Petersburg Institute of Bioregulation and Gerontology, reproduced methodological report, Tables 2–3
20 elite female rhythmic gymnasts. Combination n=12; usual training n=8.
Morning recovery heart rate decreased from 83.8 to 74.2 beats/min in the combined arm. Heart rate during full routines and individual elements showed no significant change.
- [EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION]. ↗
2015 · Uncontrolled human report
Adults aged 41–83 with multiple conditions and organic brain syndrome in remission
The authors reported changes in biological-age indicators after Pinealon and Vesugen. They also reported prooxidant activity and lower circulating CD34-positive cell markers.
Animal models
- Investigation of antihypoxic properties of short peptides ↗
2008 · Journal publication · Synthetic peptide / defined-sequence research
Experimental hypobaric/prenatal hypoxia models
The comparative report describes antihypoxic activity, with the largest effect for Pinealon in the tested model.
- Neuroprotective Effects of Tripeptides—Epigenetic Regulators in Mouse Model of Alzheimer’s Disease ↗
2021 · Animal / experimental
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
5xFAD mouse model and neuronal research
Peptides showed no significant LTP restoration. Pooled total spine density differed with EDR but not KED; effects varied by sex and spine subtype.
9 more studies
- Pinealon after maternal hypoxia: offspring and adult-rat findings ↗
2008 · Original journal publication · Pinealon in maternal arm; separate adult-male Vilon, Vesugen, Pinealon and Epitalon arms
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Pregnant rats exposed to hypoxia on gestation day 10; separate adult-male experiment, n=10/group; offspring open-field strata n=6, 11, 9 and 12
Pinealon-treated hypoxic dams had 14±2 offspring versus 9±3 with saline (p<0.05). Offspring activity and neuronal responses changed. Adult-rat Table 1 reports 10% mortality with both Pinealon and saline, conflicting with the narrative claim of higher Pinealon mortality.
- Pinealon during gestation: survival, learning and caspase-3 ↗
2012 · Original journal publication · pinealon
Offspring of prenatally hypoxic rats, tested at 21 days; sample sizes absent from accessible abstract
The publisher abstract reports improved newborn survival and reduced learning disruption after maternal Pinealon, with effects varying by hypoxia timing. It gives no numerical treatment effect or group denominator.
- Pinealon, Cortexin and Deltaran: prenatal-stress conference findings ↗
2014 · Conference abstract · Cortexin mixture, Pinealon and Deltaran (DSIP-containing formulation); separate groups
21-day-old outbred rat offspring; seven listed treatment groups; no group sizes supplied
The abstract reports 96% survival with Deltaran and 94% with Pinealon, without denominators or an untreated-hypoxia survival rate. Learning favored Deltaran then Pinealon then Cortexin, but contradictory caspase-3 statements remain unresolved.
- Pinealon versus Cortexin after prenatal hypoxia: dissertation methods ↗
2013 · Dissertation author-abstract transcription · pinealon, cortexin
Young-rat prenatal arm and a separate 120-old-male ischemia arm; prenatal Table 2 contains two n values per group with unclear hierarchy
For gestation-day-13–20 hypoxia, third-day maze latency was 34.5±3.9 seconds with Pinealon, 58.37±3.22 with Cortexin and 121.8±19.01 with saline. Cortexin-only offspring also performed worse than intact controls. Source is an author-abstract transcription, not an authenticated full thesis.
- Pinealon and hypothalamic norepinephrine rhythms in female rats ↗
2014 · Original journal publication · pinealon
Female rats with methionine-induced hyperhomocysteinemia; pregnancy not established
The publisher abstract reports correction of altered diurnal norepinephrine dynamics in the medial preoptic hypothalamic area. It does not provide n, numerical concentrations or pregnancy outcomes.
- Pinealon protects the rat offspring from prenatal hyperhomocysteinemia ↗
2012 · Original journal publication · Pinealon (Glu-Asp-Arg / EDR), Garmonika, Russia
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Six litters per group; 23 offspring/group in water-maze testing; plasma homocysteine subsets n=5, 4 and 4
At day 10, pups weighed 25.03±4.86 g with maternal Pinealon plus methionine versus 17.86±3.05 g with methionine alone. First-trial maze latency improved partly, but homocysteine stayed elevated and all groups converged by trial five.
- [Effects of introduction of short peptides before carotid artery occlusion on behaviour and caspase-3 activity in the brain of old rats]. ↗
2011 · Animal / experimental
Old rats given peptides before carotid-artery occlusion
The report describes increased behavioral sleep and reduced exploratory, motivational and motor behavior after Pinealon pretreatment. It also reports a survival signal across peptide treatment and changes in caspase-3.
- [Effect of peptide geroprotectors on the navigation system learning and caspase-3 in brain structures in rats of different age]. ↗
2013 · Animal / experimental
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Young and old rats tested in the Morris water maze
Pinealon showed a greater positive learning effect than Cortexin in this experiment, accompanied by regional changes in brain caspase-3.
- Investigation of the actoprotective properties of the tripeptide Pinealon ↗
2015 · Animal / experimental
24 five-month-old male outbred rats (250–300 g), four groups; three treadmill groups and one vivarium control
Treadmill time improved in all training arms. The authors report day-10 increases of 18 minutes with Pinealon and 13.8 minutes with Metaprot relative to their own baselines.
Cell / tissue models
- Biological activity of regulatory peptides in model experiments in vitro ↗
2008 · Journal publication · Synthetic peptide / defined-sequence research
Lipoprotein, erythrocyte and neuronal model experiments
The peptides did not behave as direct antioxidants. Effects on lipid peroxidation, membrane stability and neuronal survival differed by peptide.
- Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes. ↗
2024 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Induced cortical neurons derived from older human donors’ fibroblasts
EDR reduced oxidative DNA damage and promoted dendritic branching. The tested tripeptides did not improve mitochondrial or lysosomal activity or change p16 levels.
4 more studies
- Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. ↗
2011 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Cerebellar granule cells, neutrophils and PC12 cells
Pinealon reduced stress-associated reactive oxygen species and necrotic cell death, alongside changes in ERK activation and cell-cycle behavior.
- Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture. ↗
2011 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Organotypic pineal-gland cultures from three-month-old rats
EDR did not change the apoptosis marker AIF. The reported stimulation of CGRP expression occurred only with AEDG (Epitalon), not EDR (Pinealon).
- Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction. ↗
2019 · In vitro
Purified DNA, spectroscopy, NMR and molecular-dynamics experiments
EDR interacted with DNA in the tested systems; magnesium promoted the interaction. The authors described partial entry into the major groove and contacts with guanine atoms.
- Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. ↗
2011 · Original journal report · Defined synthetic peptides tested in cell uptake or DNA-binding assays
HeLa cells and nucleic-acid fluorescence assays
Fluorescent Epitalon, Pinealon and Testagen entered HeLa cells and nuclei. Separate fluorescence assays found sequence-dependent DNA binding, including for Bronchogen.
The rail study measured functional indicators. The truck-driver study tested a combination of peptides.
Composition, reviews & other sources (8)
- Identification of short peptides in the composition of polypeptide complexes isolated from animal organs ↗
2020 · Analytical / composition study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
- Pinealon plus Chonsurid: dental bone-healing method — RU2589264C2 ↗
2016 · Patent publication · Patent-defined substance or composition
6 more sources
- Pinealon / EDR: post-injury neurological use — US8524674B2 ↗
2013 · Patent publication · Patent-defined substance or composition
- Neuroprotective effects of peptides bioregulators in people of various age ↗
2013 · Review
- Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression ↗
2013 · Review
- EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease ↗
2020 · Review
- Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease ↗
2022 · Review
- Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters ↗
2023 · Study design unresolved
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
Sources with open questions (2)
- Pinealon + Crystagen: gymnast combination report ↗
Lead · original evidence not verified
- Laboratory-code dictionary acquisition ↗
Lead · original evidence not verified
Pineamin ↗
Pineal / menopause / reproductive research · Tissue extract
8 human reports · 1 animal models
At 90 days, the trial reported a symptom-category response in 59.1% of Pineamin recipients versus 36.7% with placebo.
Studies and sources
Sequence or preparation · Polypeptide mixture; no single sequence
Related preparation · Bovine pineal polypeptide fractions. Distinct preparation from Epithalamin; not synthetic Epitalon or Pinealon.
Human reports
- Recent tendencies in the prevention and treatment of menopausal syndrome ↗
2016 · Original clinical report · Pineamin tissue-derived polypeptide mixture
120 postmenopausal women aged 45–60; placebo 30, one-course group 30, two-course group 60
At 90 days, the trial reported a symptom-category response in 59.1% of Pineamin recipients versus 36.7% with placebo.
- Pineamin increased pineal melatonin synthesis in elderly people ↗
2017 · Original human biomarker report · Pineamin polypeptide complex
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
55 older patients with reduced pineal melatonin function
A 55-person report in older adults with reduced melatonin production found 1.9-fold higher nighttime urinary melatonin-metabolite excretion after Pineamin. It did not quantify a sleep improvement.
6 more studies
- Efficacy of non-hormonal therapy in women with climacteric syndrome ↗
2021 · Randomized trial · Pineamin, a pineal-gland polypeptide mixture, administered intramuscularly; placebo comparator.
94 postmenopausal women: Pineamin 46, placebo 48
The double-blind multicenter report found greater improvements in menopausal symptom and quality-of-life scores with Pineamin. Participants reported faster sleep onset and fewer nighttime awakenings; urinary melatonin sulfate was higher than with placebo.
- Combined therapy including Pineamin in postmenopausal women: open randomized controlled study ↗
2020 · Randomized trial · Pineamin polypeptide mixture added to estradiol/dydrogesterone; comparison with the same hormonal treatment alone.
40 women with severe menopausal symptoms; 12-week comparison
Both hormonal-treatment groups improved. The Pineamin add-on group had lower symptom scores, while several between-group biomarker and daily-impact comparisons were not significant.
- Therapeutic options for autonomic symptoms and anovulation in premature ovarian insufficiency ↗
2019 · Human comparative study · Pineamin polypeptide preparation, studied alone and with estrogen/progestogen; a hormone-only group was also included.
66 women, three groups of 22
Corpora lutea were observed in 13 women receiving Pineamin with estrogen/progestogen, one receiving hormone therapy alone, and none receiving Pineamin alone. The abstract reports no significant between-group differences in LH, FSH or AMH, despite within-group hormonal changes.
- Follicular melatonin as a predictor of assisted reproduction outcomes in anovulatory infertility ↗
2022 · Uncontrolled human report · Pineamin polypeptide preparation in a subset of the low-ovarian-reserve group before assisted reproduction; not all participants received Pineamin.
150 women in three groups; every third participant in the low-reserve group received Pineamin
Follicular melatonin correlated with mature-oocyte and high-quality-embryo measures. The low-reserve group, only partly exposed to Pineamin, had the highest mean follicular melatonin.
- Pineamin and ejaculate quality and symptoms associated with male aging ↗
2025 · Randomized trial · Pineamin polypeptide preparation compared with L-carnitine in the male pilot study.
60 men with pathozoospermia; Pineamin versus L-carnitine; three months
Semen parameters improved more with Pineamin than with L-carnitine in a small open comparison. Pregnancy and live-birth outcomes were not tested.
- Pineamin in combined therapy for diminished ovarian reserve ↗
2026 · Randomized trial · Pineamin polypeptide preparation added to estrogen/progestogen in the diminished-ovarian-reserve comparison.
70 women: adjunctive Pineamin 36, comparison 34
In a 70-person open randomized adjunctive study, IVF pregnancies were reported in 14/36 women receiving Pineamin with hormone therapy versus 6/34 receiving hormone therapy alone. These were pregnancies, not live births.
Animal models
- Kim’s five-peptide comparison in animal stress experiments ↗
2024 · Dissertation
Separate animal pharmacology experiments; participant-level and group-level counts for the five preparations unavailable
The chapter identifies Cortexin, Pineamin, Prostatilen, Thymalin and Thymogen. The author highlights Pineamin in conclusions; original outcome tables and dose schedules have not been recovered.
Sleep symptoms, semen measures and IVF pregnancies are distinct endpoints. These findings do not establish live-birth benefit or longevity.
Composition, reviews & other sources (2)
- Amino-acid analysis of Pineamin and three organ peptide preparations ↗
2017 · Original journal article · Free and hydrolysis-released amino acids; the measurements do not identify intact peptide sequences.
- Pineamin: polycystic-ovary syndrome use — RU2732688C1 ↗
2020 · Patent publication · Patent-defined substance or composition
Prostamax ↗
Prostate · Synthetic peptide
3 cell / tissue models
Reports tissue-specific growth responses to the corresponding synthetic peptides in organotypic cultures.
Studies and sources
Sequence or preparation · KEDP
Related preparation · Prostatilen is a distinct extract. Tissue association does not establish product equivalence.
Cell / tissue models
- The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats ↗
2006 · Journal publication · Synthetic peptide / defined-sequence research
Heart, lung, prostate and pancreatic explants from young and old rats
Reports tissue-specific growth responses to the corresponding synthetic peptides in organotypic cultures.
- Effects of short peptides on lymphocyte chromatin in senile subjects ↗
2004 · Journal publication · Defined synthetic peptides
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Leukocytes sampled from people aged 75–88 years and exposed to peptides in culture.
Five short peptides increased ribosomal-gene activity and altered condensed chromatin in sampled leukocytes. Epitalon, Livagen and Prostamax changed chromosome-1 pericentromeric chromatin; Epitalon and Livagen also changed chromosome 9.
1 more studies
- Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro) ↗
2012 · Journal publication · Defined synthetic peptide
Cultured cells from donors aged 75–86 years.
Prostamax increased sister-chromatid exchanges from 5.9 ± 0.2 to 12.0 ± 0.28 per cell and silver-positive nucleolar organizer regions from 0.95 to 2.5 per cell. These are chromatin assays, not prostate-symptom outcomes.
Prostatilen patient reports do not establish clinical efficacy of synthetic Prostamax.
Composition, reviews & other sources (2)
- Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression ↗
2013 · Review
- Prostamax: KEDP molecular and prostate-use claims — RU2177802C1 ↗
2002 · Patent publication · Patent-defined substance or composition
Prostateks ↗
Prostate · Tissue extract
2 human reports
Urinary symptom, quality-of-life and urine-flow measures improved in both postoperative groups. The Prostateks adjunct group reported larger improvements at one and three months.
Studies and sources
Sequence or preparation · Prostate-extract mixture
Related preparation · Geropharm prostate-extract preparation. Not equivalent to synthetic Prostamax or every Prostatilen formulation.
Human reports
- Prostate extract after transurethral resection for benign prostatic hyperplasia ↗
2022 · Human comparative study · Prostateks prostate extract, administered rectally as an adjunct to postoperative treatment including tamsulosin.
127 men after bipolar prostate resection: adjunctive Prostateks 60, tamsulosin-only comparison 67
Urinary symptom, quality-of-life and urine-flow measures improved in both postoperative groups. The Prostateks adjunct group reported larger improvements at one and three months.
- Complex treatment of patients with chronic bacterial prostatitis using biologically active peptides ↗
2022 · Journal publication · Prostateks rectal suppository preparation; not Prostatilen, Prostamax or Prostateks Plus
94 chronic bacterial prostatitis patients aged 21–45; 47 antibiotic-only and 47 antibiotic plus Prostateks suppositories.
The Prostateks add-on group had 91.4% microflora eradication and a reported 89.8% increase in mean volumetric urine flow. Symptom scores improved more than with antibiotic alone, but the abstract does not provide the score changes or control eradication rate.
Postoperative adjunct comparison; no isolated or general fertility effect established.
Prostatilen ↗
Prostate · Tissue extract
7 human reports · 2 animal models · 1 cell / tissue models
An uncontrolled 307-person chronic-prostatitis series reported symptom disappearance or attenuation in 96.7% after Prostatilen.
Studies and sources
Sequence or preparation · Mixture
Related preparation · Prostate-derived preparation. Separate from Prostamax.
Human reports
- The use of prostatilen in treating patients with chronic prostatitis ↗
1991 · Uncontrolled human report
307 men with chronic prostatitis
An uncontrolled 307-person chronic-prostatitis series reported symptom disappearance or attenuation in 96.7% after Prostatilen.
- The use of prostatilen in treating patients with prostatic diseases ↗
1991 · Uncontrolled human report
37 patients with chronic prostatitis and 15 with prostatic adenoma
Describes changes in symptoms, urinary measures and reproductive-function measures with Prostatilen.
5 more studies
- Prostatilen AC: three-month sperm DNA fragmentation follow-up ↗
2018 · Original journal report · Prostatilen AC rectal suppositories with prostate extract and zinc arginyl glycinate
35 men aged 21–46 with chronic nonbacterial prostatitis, reproductive disturbances and a partner with a history of missed miscarriage.
Mean sperm DNA fragmentation fell from 17.8% to 7.5% at month one, then rose to 10.2% at month two and 16.2% at month three. The month-three change from baseline was statistically inconclusive.
- Prostatilen AC: Phase IV placebo-controlled study of sperm DNA fragmentation ↗
2022 · Original journal report · Prostatilen AC, 30 mg prostate extract plus 180 mg zinc arginyl glycinate per suppository
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
90 men aged 25–45 with infertility and elevated sperm DNA fragmentation, randomized 45:45 from 183 screened.
Sperm DNA fragmentation was lower after the first 10-day course with Prostatilen AC versus placebo (p = 0.000022). After a second course, medians were 6.91% in the two-active-course group and 14.56% in the placebo-then-active group.
- Prostatilen AC and infrared laser therapy in 97 men with idiopathic infertility ↗
2023 · Original journal report · Prostatilen AC rectal suppositories, alone or with low-intensity infrared laser
97 men with idiopathic infertility, randomized to laser (34), Prostatilen AC (31), or both treatments (32).
At two months, progressive sperm motility rose from 29.2% to 37.1% with the combination, versus 28.6% to 33.3% with laser and 31.8% to 36.4% with Prostatilen AC alone. The authors reported a greater change with the combination (p < 0.01).
- Four intranasal peptide arms at simulated 4,500 m ↗
2014 · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12
Men aged 20–25 with asthenic or immune-status features. Four active arms of 6–8 each and 11 saline controls.
Thymogen was associated with lower lactate during the chamber protocol. Cortexin showed longer complex reaction latency alongside other physiological changes. The endpoints were heterogeneous.
- Cheprasov’s Medilab peptide comparisons in aerospace stress ↗
1997 · Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods
116 men across three stress comparisons (30, 70 and 16), plus an eight-cosmonaut comparison within the reported dissertation program of 328.
The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.
Animal models
- Thymogen and four peptide preparations in hypoxia, heat and cold ↗
2018 · Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11
Outbred male mice in the single-dose hypoxia screen; male rats (180–210 g) in the repeated-dose hypoxia table. Separate temperature experiments.
In the three-day rat comparison, Thymogen at 0.1 mg/kg gave 28.6±11.8 min versus 2.2±0.1 with saline. All 16 arms and their reported values match the 2014 monograph. Thymogen had no significant benefit on the air-cooling endpoint.
- Kim’s five-peptide comparison in animal stress experiments ↗
2024 · Dissertation
Separate animal pharmacology experiments; participant-level and group-level counts for the five preparations unavailable
The chapter identifies Cortexin, Pineamin, Prostatilen, Thymalin and Thymogen. The author highlights Pineamin in conclusions; original outcome tables and dose schedules have not been recovered.
Cell / tissue models
- [POLYPEPTIDES INFLUENCE ON TISSUE CELL CULTURES REGENERATION OF VARIOUS AGE RATS]. ↗
2015 · Original journal report
Organotypic tissue cultures from young and old rats
Calf-tissue preparations, including Ventvil, stimulated corresponding tissue-culture growth with changes in proliferation-related markers.
Original clinical methods and comparators need appraisal; extract results do not establish synthetic KEDP efficacy.
Composition, reviews & other sources (2)
- Prostatilen: smooth-muscle use claims — RU2058780C1 ↗
1996 · Patent publication · Patent-defined substance or composition
- Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results ↗
2013 · Review
Retinalamin ↗
Retina · Tissue extract
12 human reports · 1 animal models
Compares administration routes of Retinalamin. Visual acuity did not change significantly; retinal-sensitivity results varied by disease stage and follow-up.
Studies and sources
Sequence or preparation · Mixture
Related preparation · Retinal tissue preparation. No equivalence to Normophthal established.
Human reports
- Peptide bioregulators: delivery and efficacy ↗
2020 · Human comparative study
Open-angle glaucoma; 498 patients (eyes), as worded in the abstract
Compares administration routes of Retinalamin. Visual acuity did not change significantly; retinal-sensitivity results varied by disease stage and follow-up.
- Structural and functional changes in the retina of patients with primary open-angle glaucoma and compensated intraocular pressure while undergoing retinoprotective therapy ↗
2019 · Randomized trial · Retinalamin tissue-derived preparation
180 glaucoma patients (355 eyes), randomized equally; 12 months
Visual-field indices improved within the treated group while declining in controls. Visual acuity did not change; retinal nerve-fiber thickness and neuroretinal-rim volume remained stable in both groups. Electrophysiological results varied by measure.
10 more studies
- The influence of long-term retinal protective therapy on glaucoma progression according to structural and functional tests ↗
2020 · Randomized trial · Retinalamin tissue-derived preparation
147 patients (249 eyes), randomized; 24 months
Retinal nerve-fiber thickness remained stable within the treated group and declined within controls, but endpoint differences between groups were not significant. Visual acuity and mean deviation did not significantly change; pattern standard deviation worsened in both groups.
- Neuroprotective therapy in advanced primary open-angle glaucoma ↗
2025 · Uncontrolled human report · Retinalamin tissue-derived preparation
56 patients (98 eyes), advanced glaucoma; prospective two-center cohort, 2022–2024
The treated cohort had smaller annual declines in visual-field mean deviation and retinal nerve-fiber thickness than untreated controls. Intraocular pressure was controlled in both groups.
- Retinalamin in diabetic retinopathy: three-month imaging and electrical responses ↗
2024 · Original journal report · Intramuscular Retinalamin (Geropharm)
56 people with type 1 or type 2 diabetes and retinopathy without active macular edema. Retinalamin and comparison arms each included 28 people (56 eyes).
At three months, mean ganglion-cell complex thickness went from 105.45 to 109.14 µm with Retinalamin and from 103.46 to 101.50 µm in controls. The paper reports p = 0.047 for change within the treated group.
- Retinalamin versus placebo over two years in 21 patients with age-related macular degeneration ↗
2026 · Original journal report · Repeated intramuscular Retinalamin versus placebo
21 people, each with dry AMD in one eye and wet AMD in the other. Retinalamin: 11 people (22 eyes). Placebo: 10 people (20 eyes).
At 720 days, mean light sensitivity in dry AMD eyes rose by 3.27 dB with Retinalamin and fell by 4.14 dB with placebo, a reported difference in change of 7.41 dB (p < 0.001). In treated wet AMD eyes, the within-group increase was statistically inconclusive (p = 0.302).
- Retinalamin in retinal dystrophy: a 46-patient long-term comparison ↗
2015 · Original journal report · Parabulbar Retinalamin, repeated courses
46 patients (92 eyes): 20 received Retinalamin for 5–7 years, 11 for 23–25 years, and 15 received conventional care.
Visual acuity improved after the first course in 18/31 Retinalamin recipients and 4/15 comparison patients. After 23–25 years, 6/9 patients with pigmentary retinal dystrophy in the longer-treatment group had residual or object vision versus 0/11 comparison patients.
- Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration ↗
2021 · Original journal report · Temporal paravascular Retinalamin injections with or without Cortexin and Ventfort Lingval by electrophoresis
38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.
Visual acuity went from 0.71 to 0.76 with Retinalamin alone and from 0.76 to 0.88 with the combination. This comparison used electrophoresis for the two added preparations.
- Normophthal added to Retinalamin for early age-related macular degeneration ↗
2013 · Dissertation author abstract · Oral Normophthal after injected Retinalamin versus injected Retinalamin alone
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
120 patients with early age-related macular degeneration, 213 eyes: 67 in the combination group and 53 in the Retinalamin group.
After 40 days, uncorrected visual acuity in the 45–59-year subgroup was 0.62 with adjunctive Normophthal and 0.60 with Retinalamin alone. The author reports no significant additional clinical effect in the oldest subgroup.
- One versus two Retinalamin courses in dry age-related macular degeneration ↗
2016 · Human comparative study
90 adults aged 47–75 with dry AMD, contributing 180 eyes. One course: 30 people. Repeat course: 60 people.
In 90 patients, the authors reported improved retinal electrical responses in 80% of early or intermediate cases after treatment. More than 70% of atrophic cases improved after the repeat course.
- Retinalamin schedules and visual-field testing in advanced glaucoma ↗
2022 · Human comparative study
17 adults with advanced primary open-angle glaucoma, 34 eyes. Nine received courses every three months and eight every six months.
Retinal photosensitivity did not change significantly in this 17-patient schedule comparison. Both groups received Retinalamin.
- Retinalamin schedules and OCT measurement agreement in advanced glaucoma ↗
2024 · Human comparative study
17 adults, 34 eyes. Nine patients on the three-month schedule and eight on the six-month schedule.
Baseline agreement between OCT devices for retinal nerve fiber layer thickness was 0.69 in manual mode and 0.73 in automatic mode. Agreement for macular volume was 0.21 in both modes.
Animal models
- Retinoprotective effects of Retinalamin studied in an experimental model of photochemical damage to rabbit retinas ↗
2021 · Animal / experimental · Retinalamin tissue-derived preparation
36 rabbits (72 eyes), four randomized groups
Retinalamin did not significantly improve electroretinography, retinal morphology or apoptosis measures versus saline in this photochemical retinal-injury model.
Clinical studies have mixed structural and functional findings; the rabbit photochemical-injury experiment was negative. These studies tested Retinalamin.
Composition, reviews & other sources (5)
- RetinGero dry AMD trial: protocol and preliminary enrollment ↗
2025 · Published trial protocol and recruitment update
- Amino-acid analysis of Pineamin and three organ peptide preparations ↗
2017 · Original journal article · Free and hydrolysis-released amino acids; the measurements do not identify intact peptide sequences.
3 more sources
- Retinalamin plus Cortexin: optic-nerve and retinal method — RU2373904C1 ↗
2009 · Patent publication · Patent-defined substance or composition
- Retinalamin / Cortexin: local ocular delivery method — RU2195297C2 ↗
2002 · Patent publication · Patent-defined substance or composition
- Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results ↗
2013 · Review
Sigumir ↗
Named tissue preparation · Tissue extract
2 human reports
The 2005–2006 report describes symptom changes over 30–45 days, without substantial radiographic improvement. The English brochure repeats its cohort and percentages under Cartalax; preparation attribution and cohort independence are unresolved.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Sigumir: clinical report on a tissue-derived preparation ↗
2006 · Institute report — commercial reproduction · Tissue-derived mixture / named preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
64 patients: 33 adjunctive Sigumir; 31 controls. Knee osteoarthritis, spinal degeneration or osteoporosis.
The 2005–2006 report describes symptom changes over 30–45 days, without substantial radiographic improvement. The English brochure repeats its cohort and percentages under Cartalax; preparation attribution and cohort independence are unresolved.
- Application of bioregulating therapy in complex treatment of temporomandibular joint diseases in people of elderly and senile age ↗
2012 · Journal publication · Named tissue-derived preparation
62 older patients with temporomandibular joint diseases
The indexed abstract describes adjunctive Sigumir in older patients with temporomandibular joint disease. Full clinical appraisal remains pending.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
Slavinorm / Vasolin ↗
Blood vessels · Tissue extract
5 human reports · 3 animal models
Pain-free walking distance rose 46.2% and 31.4% in the two Slavinorm groups versus 6.5% with placebo.
Studies and sources
Sequence or preparation · Calf-vessel polypeptide complex
Related preparation · Vascular polypeptide preparations. The Slavinorm trials used the branded extract. The composition study detected KED in a vascular extract.
Human reports
- Slavinorm for intermittent claudication: randomized placebo-controlled trial ↗
2023 · Original clinical journal publication · Slavinorm, bovine-vessel polypeptide complex
108 randomized patients; active groups 36/36, placebo groups 18/18
Pain-free walking distance rose 46.2% and 31.4% in the two Slavinorm groups versus 6.5% with placebo.
- Slavinorm in peripheral arterial atherosclerosis: 78-patient comparison ↗
2025 · Original clinical journal publication · Slavinorm; comparator received baseline care and pentoxifylline
78 patients: 38 Slavinorm plus baseline care, 40 comparator; diabetes excluded
At three months the ankle–brachial index was 0.8 with Slavinorm and 0.7 with pentoxifylline. In the Slavinorm group, 22 of 38 participants walked 35–40 m farther.
3 more studies
- Slavinorm after above-knee femoropopliteal bypass: twelve-month comparison ↗
2026 · Original clinical journal publication · Slavinorm bovine-vessel polypeptide complex plus standard care
Author affiliations · Ryazan State Medical University
60 postoperative patients, 30 per arm; Fontaine III–IV disease
Walking distance and ankle–brachial index were higher in the adjunctive group at twelve months; the abstract contains inconsistent restenosis figures.
- Vascular polypeptides plus troxerutin in chronic venous disease: randomized trial ↗
2026 · Original clinical journal publication · Bovine-vessel polypeptide complex; brand not named in the abstract
190 randomized participants, 95 per arm; both arms received troxerutin
The abstract reports lower venous severity with adjunctive polypeptides than placebo.
- Vascular polypeptides during rehabilitation after myocardial infarction with type 2 diabetes ↗
2026 · Original clinical journal publication · Slavinorm 5 mg bovine-vessel polypeptide lyophilizate for intramuscular injection.
58 patients: 29 adjunctive polypeptides plus rehabilitation, 29 rehabilitation alone; conducted in 2025
In 58 patients after myocardial infarction, median pain-free walking distance at day 50 was 260 vs 190 m with Slavinorm plus rehabilitation versus rehabilitation alone. Six of 29 Slavinorm recipients had injection-site pain.
Animal models
- Slavinorm and cortical microcirculation in older hypertensive rats ↗
2017 · Animal / experimental · Slavinorm, calf-vessel polypeptide complex
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
41 male rats: 12 treated hypertensive, 19 untreated hypertensive, 10 normotensive controls
Cortical microvessel density was about 1.7 times that of untreated hypertensive rats two months after one course. Perfusion rose but remained below that of normotensive rats.
- Slavinorm and cortical microcirculation after one or two courses in hypertensive rats ↗
2017 · Animal / experimental · Slavinorm, calf-vessel polypeptide complex
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
Four groups of hypertensive male rats (6, 14, 6 and 14), with a normotensive reference group
After two courses, older rats had about 1.6 times the cortical microvessel density and about 15% higher perfusion than untreated hypertensive rats of the same age.
1 more studies
- Vessel polypeptides and vascular markers in rabbits of different ages: 2025 conference abstract ↗
2025 · Original conference abstract; not a full journal article · Vessel-derived polypeptide preparation; Slavinorm brand not verified
40 rabbits: four groups of ten, each with five young and five older animals
Vascular-marker and plaque findings were reported in an age-stratified rabbit experiment.
The arterial, venous and postoperative studies enrolled different populations. The venous trial abstract describes a bovine-vessel complex without naming the brand. Purified KED has its own evidence.
Composition, reviews & other sources (4)
- Identification of short peptides in the composition of polypeptide complexes isolated from animal organs ↗
2020 · Analytical / composition study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
- Polypeptide vessel complex and its role in physiology function regulation in aging pathology ↗
2019 · Review
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
2 more sources
- Peptidergic regulation of age-related alterations in the cardiovascular system ↗
2026 · Journal publication
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
- Slavinorm: critical limb-ischemia method — RU2827088C1 ↗
2024 · Patent publication · Patent-defined substance or composition
Stamakort ↗
Named tissue preparation · Tissue extract
1 human reports
Fasting total gastric acidity was 37.1 mmol/L after Stamakort plus conventional therapy versus 31.4 mmol/L with conventional therapy alone.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Stamakort: institute clinical report (commercially hosted translation) ↗
2011 · Institute report — commercial reproduction · Tissue-derived mixture / named preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
47 patients with chronic gastritis: 30 adjunctive preparation, 17 conventional-care controls
Fasting total gastric acidity was 37.1 mmol/L after Stamakort plus conventional therapy versus 31.4 mmol/L with conventional therapy alone.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
Suprefort ↗
Named tissue preparation · Tissue extract
2 human reports
In the diabetes subgroup, two-hour glucose was 7.0 mmol/L with Suprefort versus 9.4 mmol/L with usual care. Pancreatic enzyme changes in the separate pancreatitis subgroup were reported as trends.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Suprefort: clinical report on a tissue-derived preparation ↗
2006 · Institute report — commercial reproduction · Tissue-derived mixture / named preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
59 patients: pancreatitis 12 treated/8 controls; type-2 diabetes 22 treated/17 controls.
In the diabetes subgroup, two-hour glucose was 7.0 mmol/L with Suprefort versus 9.4 mmol/L with usual care. Pancreatic enzyme changes in the separate pancreatitis subgroup were reported as trends.
- Suprefort with and without Cerluten and Endoluten in type 2 diabetes ↗
2013 · Conference report · company reproduction · Oral pancreas, brain and pineal polypeptide preparations added to standard therapy
918 adults aged 52–65 with type 2 diabetes: 329 standard care, 214 added Suprefort, 375 added Suprefort, Cerluten and Endoluten.
The conference report lists two-hour glucose of 9.7 mmol/L with standard care, 7.3 with added Suprefort, and 6.5 with the three-product combination.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
Svetinorm ↗
Named tissue preparation · Tissue extract
2 human reports
Bilirubin was 20.1 µmol/L after adjunctive Svetinorm and 23.6 µmol/L after conventional care. The table marks a change from the shared baseline of 27.1 µmol/L.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Svetinorm: clinical report on a tissue-derived preparation ↗
2006 · Institute report — commercial reproduction · Tissue-derived mixture / named preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
85 patients: 47 adjunctive Svetinorm; 38 controls. Chronic hepatitis or care following radiation/chemotherapy.
Bilirubin was 20.1 µmol/L after adjunctive Svetinorm and 23.6 µmol/L after conventional care. The table marks a change from the shared baseline of 27.1 µmol/L.
- Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis ↗
2013 · Conference report · company reproduction · Oral vascular, brain, liver and pineal polypeptide preparations added to standard therapy
1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.
The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
Tactivin ↗
Immune research · Tissue extract
4 human reports · 1 animal models
Adjunctive Tactivin was reported to improve cellular immunity and reduce infectious complications 1.77-fold. The abstract gives no raw infection counts or comparison-arm sizes.
Studies and sources
Sequence or preparation · Thymus-derived preparation; not a single defined sequence
Related preparation · Historical thymus-preparation research. Vilosen, Vilon, Tactivin and Thymalin are distinct preparations.
Human reports
- Clinico-immunologic effect of tactivin in chronic myeloid leukemia ↗
1994 · Journal publication · Thymus-derived polypeptide preparation
35 advanced chronic-myeloid-leukemia patients underwent immune assessment around myelosan chemotherapy.
Adjunctive Tactivin was reported to improve cellular immunity and reduce infectious complications 1.77-fold. The abstract gives no raw infection counts or comparison-arm sizes.
- Use of tactivin and imunofan for the treatment of patients with endometrial carcinoma ↗
2001 · Journal publication · Tactivin tissue extract and synthetic Imunofan as separate comparisons
Patients receiving complex treatment for endometrial adenocarcinoma; sample sizes not supplied in the indexed abstract.
Both adjunctive Tactivin and Imunofan were reported to reduce radiation complications and improve immune measures. The authors described Imunofan as somewhat more effective, without numerical rates.
2 more studies
- Imunofan and mixed herpesvirus infections in Redkin and Lyuboshenko’s 2011 comparison ↗
2011 · Original journal article
Adults with chronic recurrent infections referred to an immunologist in Omsk in 2010–2011. The methods give 35 patients per group, but list 29 women and 8 men in the Imunofan arm (37) and 25 women and 10 men in the comparison arm (35).
The paper reports clinical improvement in 73.7% with Imunofan-based care versus 57.1% with a pooled thymic-peptide comparison. Immunogram normalization was similar (85.7% versus 84.3%). Allocation followed the order patients presented, and some percentages do not match the stated counts.
- Clinical and immunologic effects of T-activin therapy in early stage melanoma patients. ↗
1996 · Human comparative study · T-activin thymus preparation
17 melanoma patients: 8 surgery plus T-activin; 9 surgery-only controls
In a 17-person melanoma comparison, the survival difference with T-activin added to surgery was not statistically significant; immune-cell changes did not track clinical benefit.
Animal models
- Thymus Polypeptide Preparation Tactivin Restores Learning and Memory in Thymectomied Rats ↗
2015 · Journal publication · Thymus-derived polypeptide preparation
Rats thymectomized at three weeks of age; active-avoidance learning assay.
Tactivin restored learning after thymectomy in young rats, whereas splenic polypeptides did not. The reported treatment was 0.5 mg/kg for one month.
Historical adjunctive reports do not isolate an extract effect. Read the source-specific formulation, comparator and numerical outcomes.
Composition, reviews & other sources (1)
- Immune-profile-directed peptide selection with psoriasis photochemotherapy — SU1674849A1 ↗
1991 · Patent publication · Patent-defined substance or composition
Taxorest ↗
Named tissue preparation · Tissue extract
1 human reports
Forced expiratory vital capacity was 3,940.5 mL with adjunctive Taxorest and 3,225.6 mL with conventional care. Significance was marked against the shared baseline.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Taxorest: clinical report on a tissue-derived preparation ↗
2011 · Institute report — commercial reproduction · Tissue-derived mixture / named preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
52 smokers with bronchitis: 31 treated, 21 controls.
Forced expiratory vital capacity was 3,940.5 mL with adjunctive Taxorest and 3,225.6 mL with conventional care. Significance was marked against the shared baseline.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
Testagen ↗
Experimental cell/DNA and avian endocrine research · Synthetic peptide
1 animal models · 1 cell / tissue models
KEDG and AEDG improved thyroid-related hormonal and morphological measures after experimental pituitary removal.
Studies and sources
Sequence or preparation · KEDG — primary paper PMID 22117547
Related preparation · Not established. Primary publication explicitly identifies Testagen as Lys–Glu–Asp–Gly.
Animal models
- [Effects of Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly peptides on hormonal activity and thyroid morphology in hypophysectomized mature and old birds]. ↗
2011 · Original journal report
Mature and old hypophysectomized birds
KEDG and AEDG improved thyroid-related hormonal and morphological measures after experimental pituitary removal.
Cell / tissue models
- Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. ↗
2011 · Original journal report · Defined synthetic peptides tested in cell uptake or DNA-binding assays
HeLa cells and nucleic-acid fluorescence assays
Fluorescent Epitalon, Pinealon and Testagen entered HeLa cells and nuclei. Separate fluorescence assays found sequence-dependent DNA binding, including for Bronchogen.
Identity resolved for the experimental peptide; no human testosterone or reproductive benefit established.
Composition, reviews & other sources (1)
Testoluten ↗
Named tissue preparation · Tissue extract
1 human reports
The report describes hormone and self-reported symptom changes with adjunctive treatment.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Testoluten: institute clinical report (commercially hosted translation) ↗
2011 · Institute report — commercial reproduction · Tissue-derived mixture / named preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
36 men aged 47–65: 22 adjunctive preparation, 14 nonhormonal-care controls
The report describes hormone and self-reported symptom changes with adjunctive treatment.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
Thymalin ↗
Thymus / immunity · Tissue extract
18 human reports · 6 animal models · 5 cell / tissue models
The paper reports immune and hemostatic changes during adjunctive burn treatment. The authors explicitly acknowledge that comprehensive therapy contributed to the observed changes.
Studies and sources
Sequence or preparation · Mixture
Related preparation · Thymic tissue preparation. Analytical identification of short sequences does not isolate their clinical contribution.
Human reports
- The use of thymalin for the treatment of thermal injury ↗
1983 · Human comparative study
Author affiliations · Chita Medical Institute
Patients receiving comprehensive treatment for thermal injury
The paper reports immune and hemostatic changes during adjunctive burn treatment. The authors explicitly acknowledge that comprehensive therapy contributed to the observed changes.
- Peptides of pineal gland and thymus prolong human life ↗
2003 · Human comparative study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
266 older people followed for 6–8 years
The investigators reported differences in illness and mortality across extract-treatment groups and controls. This is research on Thymalin and Epithalamin, including their combination.
16 more studies
- Cheprasov’s Medilab peptide comparisons in aerospace stress ↗
1997 · Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods
116 men across three stress comparisons (30, 70 and 16), plus an eight-cosmonaut comparison within the reported dissertation program of 328.
The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.
- Thymic peptides in Furgal’s military immunization research ↗
1996 · Dissertation
7,630 across thirteen military units in the immunocorrection series. The 240-person donor series included multiple approaches.
The donor immunization program reported 83.7% or more immune responders with thymic peptide adjuncts versus 60.5% with standard toxoid vaccination. The source does not isolate a reliable effect for either peptide.
- The lymphocyte subpopulation in patients with duodenal ulcer and the immunocorrective activity of thymalin and dalargin ↗
1998 · Original journal publication · Thymalin and Dalargin mentioned within complex therapy; simultaneous administration and the treatment arms are unresolved.
120 patients with uncomplicated duodenal ulcer; 30 healthy donors used as immune-reference controls. Treatment-arm sizes and allocation are unavailable.
The abstract reports movement of reduced T-cell rosette indices toward healthy-reference values during peptide-containing care. It does not establish which patients received each peptide or whether the pair was given together.
- Thymalin and Thymogen in gestational anemia: historical human comparisons ↗
1995 · Dissertation author-abstract transcription · Thymalin thymus-peptide mixture versus synthetic Thymogen; individual treatment-arm results unresolved
520 women in the overall research program; treatment comparisons: conventional care n=70, adjunct Thymalin/Thymogen n=140, conventional care plus heparin n=60. Separate prevention subgroup: 12 Thymalin versus 12 controls.
In the 24-woman prevention subgroup, anemia by week 36 was reported in 2/12 Thymalin-treated women versus 6/12 controls. The larger treatment program described fewer obstetric complications, but did not isolate each peptide or establish randomized effects.
- Thymalin, Epithalamin and Vilon after complicated appendicitis ↗
2008 · Original clinical journal article
Author affiliations · Chita Medical Institute
84 adults aged 18–42: 12 with uncomplicated appendicitis and 72 with postoperative wound infection. Of the 72, 62 received a peptide adjunct. Thirty healthy volunteers were a laboratory reference group.
Mean hospital stay was 24.2 days with standard care and 18.0–19.0 days in the four adjunct groups. TNF-α fell most in the Vilon cytokine subset. IL-8 increased in every measured group.
- Thymalin in patients with severe trauma ↗
1984 · Human study · design details unresolved
23 patients with severe trauma.
The authors described a better clinical course and normalization of some immune indices during complex care that included Thymalin.
- Thymalin, coagulation and recovery after deep burns ↗
2000 · Human comparative study
Author affiliations · Chita Medical Institute
32 patients with third- or fourth-degree burns treated with Thymalin.
The authors reported first skin grafting about five days earlier and a hospital stay 11 days shorter. They also described improvements in coagulation and fibrinolysis.
- Thymic peptides and microsurgery in Maksimov’s ocular-trauma program ↗
1996 · Dissertation author abstract
A mixed experimental and clinical program. The narrative describes a subgroup of 119 patients (186 eyes) with severe gunshot eye injuries.
The author reported structural and functional recovery after some combined surgical and peptide treatments. The severe injury subgroup is not a verified exposure count for either peptide.
- Thymalin and prevention of respiratory infections ↗
1988 · Indexed historical journal citation
Military personnel per the index. Sample size unavailable.
The 1988 military report examined Thymalin for respiratory infection prevention. The indexed citation provides no infection counts or comparison-group rates.
- Thymalin and immune response to influenza vaccination ↗
1988 · Indexed historical journal citation
Military personnel per the index. Sample size unavailable.
This military report examined the immune response to influenza vaccination with Thymalin. The indexed citation provides no antibody values or infection outcomes.
- Imunofan and mixed herpesvirus infections in Redkin and Lyuboshenko’s 2011 comparison ↗
2011 · Original journal article
Adults with chronic recurrent infections referred to an immunologist in Omsk in 2010–2011. The methods give 35 patients per group, but list 29 women and 8 men in the Imunofan arm (37) and 25 women and 10 men in the comparison arm (35).
The paper reports clinical improvement in 73.7% with Imunofan-based care versus 57.1% with a pooled thymic-peptide comparison. Immunogram normalization was similar (85.7% versus 84.3%). Allocation followed the order patients presented, and some percentages do not match the stated counts.
- Thymalin in a 97-patient Lipetsk schizophrenia comparison ↗
1998 · Original conference report, institute-hosted text
97 patients treated in Lipetsk from 1987 to 1996. Thymalin 27, levamisole (Decaris) 17, prodigiosan 13, laser treatment 22 and psychotropic medication alone 18.
The authors reported 25–80% improvement across symptom categories with Thymalin and 10–20% with psychotropic medication alone. These are ranges across categories. The report gives no single response rate for the 27-person Thymalin arm and includes no Imunofan group.
- [The effect of immunocorrective therapy on immunity in patients with idiopathic autoimmune cytopenias] ↗
1991 · Human study · design details unresolved
25 patients with idiopathic autoimmune cytopenias
Thymalin and glucocorticoids were investigated in an immunocorrective treatment program; the abstract reports changes in immune measures.
- [Effect of plasmapheresis and immunocorrective therapy on the status of the T-cell component of immunity in patients with autoimmune thyroiditis] ↗
1994 · Human comparative study
104 patients studied: 22 plasmapheresis alone; 82 with added Thymalin; 49 hypothyroid patients also received hormone replacement
The authors describe sustained clinical and T-cell changes after combined treatment, with follow-up over one year.
- Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients ↗
2021 · Original journal report
80 severe COVID-19 patients: 36 Thymalin and 44 saline plus standard care.
In-hospital mortality was 7/36 (19.4%) with Thymalin versus 18/44 (40.9%) with saline placebo (p=0.039). Clinical improvement was 29/36 (80.5%) versus 26/44 (59%; p=0.039).
- [A cytomorphological basis for the correction of radiation-induced immunodeficiencies and hematopoietic depression using thymus and bone marrow peptides]. ↗
1993 · Human comparative study · Preparation-specific research; no equivalence inferred
See original report; human, animal and laboratory components must be distinguished.
A mixed clinical and animal report described immune and hematopoietic recovery with several thymus/bone-marrow preparations, but does not isolate a numerical Thymogen or Thymalin treatment effect.
Animal models
- Thymogen and four peptide preparations in hypoxia, heat and cold ↗
2018 · Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11
Outbred male mice in the single-dose hypoxia screen; male rats (180–210 g) in the repeated-dose hypoxia table. Separate temperature experiments.
In the three-day rat comparison, Thymogen at 0.1 mg/kg gave 28.6±11.8 min versus 2.2±0.1 with saline. All 16 arms and their reported values match the 2014 monograph. Thymogen had no significant benefit on the air-cooling endpoint.
- Kim’s five-peptide comparison in animal stress experiments ↗
2024 · Dissertation
Separate animal pharmacology experiments; participant-level and group-level counts for the five preparations unavailable
The chapter identifies Cortexin, Pineamin, Prostatilen, Thymalin and Thymogen. The author highlights Pineamin in conclusions; original outcome tables and dose schedules have not been recovered.
4 more studies
- The effect of thymalin, dalargin and "Mucosalin" on the course of an experimental duodenal ulcer ↗
1995 · Original journal publication · Thymalin, Dalargin and experimental Mucosalin, a pig-gastric-mucosal extract; compared preparations, not a verified simultaneous pair.
80 male Wistar rats across an experimental duodenal-ulcer comparison; per-arm numbers unavailable.
The authors described protection in the order Mucosalin > Dalargin > Thymalin. The abstract gives no numerical lesion scores or combined-treatment result.
- Structural and cytochemical changes in cerebral cortical neurons of the offspring of neurosensitized female rats after prenatal administration of thymalin ↗
1989 · Original journal publication · thymalin
Offspring of neurosensitized pregnant rats; n and gestational schedule absent from abstract
Maternal Thymalin reportedly prevented cortical neuronal degeneration and cell-density loss in offspring, with age-dependent protein changes. No numerical effect sizes or reproductive-safety outcomes are supplied.
- [Correction with thymic and bone marrow peptides of radiation injuries of immuno- and hemopoiesis]. ↗
1991 · Animal / experimental · Preparation-specific research; no equivalence inferred
See original report; human, animal and laboratory components must be distinguished.
Thymus and marrow preparations were investigated in irradiated animals. The abstract describes recovery of immune and blood-forming measures.
- [The cytomorphological characteristics of hemopoiesis and of the organs of immunogenesis in exposure to thymus and bone marrow peptides during hematopoietic depression]. ↗
1989 · Animal / experimental · Preparation-specific research; no equivalence inferred
Guinea pigs with experimentally induced hematopoietic depression. The abstract gives no arm sizes.
In a guinea-pig model of bone-marrow suppression, Thymalin stimulated lymphocyte formation, Haemalin stimulated granulocyte formation, and the combined preparation Thymohaemin affected both blood and marrow measures.
Cell / tissue models
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line ↗
2022 · Journal publication · Defined peptides and Thymalin peptide complex tested separately
THP-1 leukemia-derived monocytes, differentiated macrophages and an activated HUVEC endothelial adhesion model.
Five preparations reduced LPS-induced TNF and IL-6 expression in differentiated THP-1 cells and reduced adhesion to activated endothelial cells. Chonluten also reduced monocyte TNF release; the full text notes an apoptotic cell fraction with Chonluten.
- Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells ↗
2020 · Original journal publication · Thymalin multipeptide extract; not Dalargin, not isolated Thymogen and not a clinical combination.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Human hematopoietic-cell differentiation experiment; donor count, culture size and uncertainty not provided in the abstract.
CD28 expression increased 6.8-fold, while CD44 and CD117 expression fell by a reported factor of 2–3. These are differentiation-associated markers, not a 6.8-fold increase in functional T-cell production.
3 more studies
- The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19. ↗
2023 · Original human-cell and computational journal research · Thymalin extract and isolated KE/EW dipeptides in separate cell-culture conditions; no Dalargin arm
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
PBMCs from four healthy middle-aged donors; repeated ELISA experiments and parallel samples are not additional donors
Thymalin lowered LPS-stimulated TNF-α to 44.9% and IL-1β to 37.5% of the LPS control. Stimulated IL-6 was 80.0% without a significance mark; unstimulated IL-6 increased to 79.9% versus a 20.6% resting reference.
- Combined effect of polypeptide complexes on organotypic rat tissue cultures ↗
2023 · Original journal article · Organ-derived polypeptide preparations applied directly to rat tissue in culture.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
Three-month-old Wistar rats supplied explants. Methods report 280 liver, 300 spleen and 250 kidney explants. Donor rat count is unspecified.
At 20 ng/mL, Ventvil increased the liver explant area index by 21 ± 5% versus medium alone (17 explants). Ventvil plus Thymalin gave a 20 ± 3% increase (21 explants). Ventvil alone had no significant effect in spleen explants.
- [POLYPEPTIDES INFLUENCE ON TISSUE CELL CULTURES REGENERATION OF VARIOUS AGE RATS]. ↗
2015 · Original journal report
Organotypic tissue cultures from young and old rats
Calf-tissue preparations, including Ventvil, stimulated corresponding tissue-culture growth with changes in proliferation-related markers.
Adjunctive treatment and combined-extract studies cannot isolate a particular short peptide.
Composition, reviews & other sources (9)
- Identification of short peptides: optimization of target therapeutic properties of the thymus medicine ↗
2021 · Analytical / composition study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
- From thymus extracts to synthetic thymomimetics ↗
2026 · Narrative review
7 more sources
- Thymalin combined with vaccine preparations ↗
1987 · Indexed historical journal citation
- Imunofan, Thymalin and levamisole in a historical schizophrenia citation ↗
2002 · Secondary dissertation citation
- Thymalin lineage: thymus-derived preparation — US5070076A ↗
1991 · Patent publication · Patent-defined substance or composition
- Immune-profile-directed peptide selection with psoriasis photochemotherapy — SU1674849A1 ↗
1991 · Patent publication · Patent-defined substance or composition
- Эффективность применения пептидных биорегуляторов у лиц разного возраста в условиях Крайнего Севера — Effectiveness of peptide bioregulators in people of different ages under Far North conditions ↗
2003 · Dissertation record and indexed excerpts · Thymalin, Epithalamin and Cortexin tissue-derived preparations
- [The correction of secondary radiation-induced immunodeficiencies]. ↗
1991 · Review · Preparation-specific research; no equivalence inferred
- Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results ↗
2013 · Review
Thymogen ↗
Thymus / immunity · Synthetic peptide
10 human reports · 13 animal models · 2 cell / tissue models
A 46-patient report describes lymphocyte counts moving toward reference values and higher T-cell functional activity during combined care.
Studies and sources
Sequence or preparation · EW
Related preparation · Thymalin. Composition literature discusses EW separately from KE and EDP.
Human reports
- Thymogen as an adjunct in inflammatory gynecological conditions ↗
1992 · Uncontrolled human report
46 patients with acute endomyometritis, exacerbated chronic salpingo-oophoritis or purulent tubo-ovarian disease received adjunctive Thymogen.
A 46-patient report describes lymphocyte counts moving toward reference values and higher T-cell functional activity during combined care.
- Four intranasal peptide arms at simulated 4,500 m ↗
2014 · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12
Men aged 20–25 with asthenic or immune-status features. Four active arms of 6–8 each and 11 saline controls.
Thymogen was associated with lower lactate during the chamber protocol. Cortexin showed longer complex reaction latency alongside other physiological changes. The endpoints were heterogeneous.
8 more studies
- Cheprasov’s Medilab peptide comparisons in aerospace stress ↗
1997 · Kirov Military Medical Academy doctoral dissertation author abstract, Table 1 and methods
116 men across three stress comparisons (30, 70 and 16), plus an eight-cosmonaut comparison within the reported dissertation program of 328.
The three test series covered hypoxia, motion tolerance and 24 hours of work. The abstract reports favorable task results for selected peptides and gives a tiny separate postflight Thymogen comparison.
- Thymic peptides in Furgal’s military immunization research ↗
1996 · Dissertation
7,630 across thirteen military units in the immunocorrection series. The 240-person donor series included multiple approaches.
The donor immunization program reported 83.7% or more immune responders with thymic peptide adjuncts versus 60.5% with standard toxoid vaccination. The source does not isolate a reliable effect for either peptide.
- Thymalin and Thymogen in gestational anemia: historical human comparisons ↗
1995 · Dissertation author-abstract transcription · Thymalin thymus-peptide mixture versus synthetic Thymogen; individual treatment-arm results unresolved
520 women in the overall research program; treatment comparisons: conventional care n=70, adjunct Thymalin/Thymogen n=140, conventional care plus heparin n=60. Separate prevention subgroup: 12 Thymalin versus 12 controls.
In the 24-woman prevention subgroup, anemia by week 36 was reported in 2/12 Thymalin-treated women versus 6/12 controls. The larger treatment program described fewer obstetric complications, but did not isolate each peptide or establish randomized effects.
- Thymic peptides and microsurgery in Maksimov’s ocular-trauma program ↗
1996 · Dissertation author abstract
A mixed experimental and clinical program. The narrative describes a subgroup of 119 patients (186 eyes) with severe gunshot eye injuries.
The author reported structural and functional recovery after some combined surgical and peptide treatments. The severe injury subgroup is not a verified exposure count for either peptide.
- Thymogen and acute respiratory illness in a military unit ↗
1993 · Human study · design details unresolved
Military training unit. The indexed abstract does not report arm sizes.
The abstract reports lower frequency, severity and duration of respiratory illness in a study of intranasal and subcutaneous Thymogen.
- Imunofan and mixed herpesvirus infections in Redkin and Lyuboshenko’s 2011 comparison ↗
2011 · Original journal article
Adults with chronic recurrent infections referred to an immunologist in Omsk in 2010–2011. The methods give 35 patients per group, but list 29 women and 8 men in the Imunofan arm (37) and 25 women and 10 men in the comparison arm (35).
The paper reports clinical improvement in 73.7% with Imunofan-based care versus 57.1% with a pooled thymic-peptide comparison. Immunogram normalization was similar (85.7% versus 84.3%). Allocation followed the order patients presented, and some percentages do not match the stated counts.
- Application thymogen for preoperative preparation of elderly patients with tumor processes in abdominal cavity ↗
2011 · Original journal report
Older adults undergoing abdominal or retroperitoneal solid-tumor surgery; sample size not supplied by the abstract.
A randomized, double-blind saline-placebo comparison reported fewer postoperative complications and a shorter postoperative period after preoperative Thymogen. The abstract provides no event counts or effect sizes.
- [A cytomorphological basis for the correction of radiation-induced immunodeficiencies and hematopoietic depression using thymus and bone marrow peptides]. ↗
1993 · Human comparative study · Preparation-specific research; no equivalence inferred
See original report; human, animal and laboratory components must be distinguished.
A mixed clinical and animal report described immune and hematopoietic recovery with several thymus/bone-marrow preparations, but does not isolate a numerical Thymogen or Thymalin treatment effect.
Animal models
- Thymogen and four peptide preparations in hypoxia, heat and cold ↗
2018 · Biomeditsina 2018(2):4–14, Tables 1–3; paired with 2014 Volume III Table 11
Outbred male mice in the single-dose hypoxia screen; male rats (180–210 g) in the repeated-dose hypoxia table. Separate temperature experiments.
In the three-day rat comparison, Thymogen at 0.1 mg/kg gave 28.6±11.8 min versus 2.2±0.1 with saline. All 16 arms and their reported values match the 2014 monograph. Thymogen had no significant benefit on the air-cooling endpoint.
- Kim’s five-peptide comparison in animal stress experiments ↗
2024 · Dissertation
Separate animal pharmacology experiments; participant-level and group-level counts for the five preparations unavailable
The chapter identifies Cortexin, Pineamin, Prostatilen, Thymalin and Thymogen. The author highlights Pineamin in conclusions; original outcome tables and dose schedules have not been recovered.
11 more studies
- GHK, Dalargin and Thymogen in experimental bone fracture: 2021 rat study ↗
2021 · Original preclinical journal study; not a literature review · Copper-free GHK, Dalargin and Thymogen, singly and in pairs; local intraosseous administration
Male Wistar rats with experimental femoral fracture; Table 1 lists eight groups, n=8/group; overall cohort flow not separately specified
At day 10, GHK plus Dalargin had a phagocytic index of 71.3±5.1% versus 30.8±3.1% in fracture controls. GHK alone did not significantly improve oxygen-dependent neutrophil reserve. Bone-repair findings were qualitative.
- The immunoregulatory and hepatotropic action of Gly-His-Lys and Timogen ↗
2019 · Original experimental journal publication · Unbound GHK and Thymogen in separate treatment groups; not a GHK–Thymogen combination or GHK-Cu
Wistar rats, 180–220 g; tetrachloromethane and hydrazine liver-injury models. Group sizes not supplied in the three-page report.
GHK had a stronger reported hepatocyte-proliferation effect than Thymogen but suppressed antibody responses in both injury models. Thymogen normalized the response in the hydrazine model, where baseline immunity was suppressed. No numerical treatment-effect table was reported.
- GHK, Dalargin and Thymogen in rat fracture: 2014 neutrophil results ↗
2014 · Conference proceedings paper · Unbound GHK, Dalargin and Thymogen given alone or in pairwise groups.
Wistar rats (180–220 g) in a closed femoral fracture model. Table 1 lists eight groups with eight rats per group, including uninjured and fractured controls.
After ten days, 69.17% of neutrophils took up latex particles with GHK + Dalargin and 72.17% with GHK + Thymogen versus 31.67% with fracture plus saline.
- GHK and Dalargin after rat fracture: neutrophil reserve in the 2021 conference report ↗
2021 · Conference proceedings paper · Unbound GHK, Dalargin and Thymogen given alone or in pairs.
The 2021 methods report 60 Wistar rats overall, with no per-arm allocation table. The overlapping 2014 publication gives eight rats per phagocytosis group. The denominators cannot be reconciled from the reports.
GHK plus Dalargin raised the stimulated neutrophil NBT lab signal 2.9-fold and functional reserve 1.69-fold. GHK alone showed no substantial change on these oxygen-dependent measures.
- Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity. ↗
2016 · Animal / experimental · Preparation-specific research; no equivalence inferred
Intact mice, donor marrow and irradiated recipient-mouse colony assays
Five cyclic analogues, numbered 3–7, were synthesized; three showed activity in experimental hematopoietic assays. Normal-marrow stimulation and post-irradiation recovery differ. Oral activity is not a pharmacokinetic measurement.
- The effects of the EW--peptide optical and chemical isomers on the hemopoietic stem cells in intact and irradiated mice. ↗
2009 · Animal / experimental · Preparation-specific research; no equivalence inferred
See original report; human, animal and laboratory components must be distinguished.
Follow-up record on optical and chemical isomers. No abstract was recovered; overlap with earlier experiments remains unresolved.
- The effects of the EW dipeptide optical and chemical isomers on the CFU-S population in intact and irradiated mice. ↗
2007 · Animal / experimental · Preparation-specific research; no equivalence inferred
See original report; human, animal and laboratory components must be distinguished.
Optical configuration, peptide linkage and administration before or after irradiation affected colony-forming responses. Normal marrow and injury recovery are different endpoints.
- Effects of structural and "mixed" isomers of Glu-Trp dipeptide on normal hemopoietic stem cells. ↗
2006 · Animal / experimental · Preparation-specific research; no equivalence inferred
See original report; human, animal and laboratory components must be distinguished.
Glu–Trp isomers produced different colony-assay effects depending on stereochemistry and bond position. Results cannot be reduced to a universal L-stimulates/D-suppresses rule.
- [Radiation protective effect of low molecular weight thymus preparations]. ↗
1994 · Animal / experimental · Preparation-specific research; no equivalence inferred
See original report; human, animal and laboratory components must be distinguished.
The abstract discusses low-molecular-weight thymic preparations in radiation injury; it does not provide enough methods to establish a human controlled study.
- [Radioprotective effect of synthetic immunomodulators on hemopoietic CFU-S]. ↗
1993 · Animal / experimental · Preparation-specific research; no equivalence inferred
See original report; human, animal and laboratory components must be distinguished.
Synthetic peptides were studied using hematopoietic colony assays after irradiation. The indexed abstract gives Thymohexin as Arg–Lys–Asp–Val–Tyr–Arg; the conflicting Asn/RKNVYR rendering requires checking against original chemistry.
- [The effect of the synthetic immunomodulator thymogen on radiation-induced carcinogenesis in rats]. ↗
1992 · Animal / experimental · Preparation-specific research; no equivalence inferred
See original report; human, animal and laboratory components must be distinguished.
A long-duration radionuclide experiment in female rats reported differences in tumor occurrence. It does not establish cancer prevention or treatment in people.
Cell / tissue models
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line ↗
2022 · Journal publication · Defined peptides and Thymalin peptide complex tested separately
THP-1 leukemia-derived monocytes, differentiated macrophages and an activated HUVEC endothelial adhesion model.
Five preparations reduced LPS-induced TNF and IL-6 expression in differentiated THP-1 cells and reduced adhesion to activated endothelial cells. Chonluten also reduced monocyte TNF release; the full text notes an apoptotic cell fraction with Chonluten.
- Interaction of the synthetic immunomodulatory dipeptide bestim with murine macrophages and thymocytes ↗
2008 · In vitro
Murine macrophages, thymocytes and isolated membranes
Radiolabeled gamma-D-Glu-L-Trp bound mouse immune cells; unlabeled Thymogen competed for binding. This supports a shared binding interaction under assay conditions, not equivalent immunological outcomes in people.
Several clinical reports tested Thymogen alongside other treatments.
Composition, reviews & other sources (11)
- Identification of short peptides: optimization of target therapeutic properties of the thymus medicine ↗
2021 · Analytical / composition study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
- Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results ↗
2013 · Review
9 more sources
- Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process ↗
2014 · Journal publication · Short-peptide experimental preparations; marketed-product equivalence unresolved
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
- Thymogen in obstetrics: historical reports summarized in a monograph ↗
2007 · Historical monograph / secondary source · thymogen
- From thymus extracts to synthetic thymomimetics ↗
2026 · Narrative review
- Thymogen: L-Glu-L-Trp immune-deficiency use — US5814611A ↗
1998 · Patent publication · Patent-defined substance or composition
- GHK plus Thymogen: 2012 wound-healing patent — RU2452508C2 ↗
2012 · Patent publication · Patent-defined substance or composition
- The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples ↗
2024 · Review
- [The correction of secondary radiation-induced immunodeficiencies]. ↗
1991 · Review · Preparation-specific research; no equivalence inferred
- Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides ↗
2023 · Review · Defined synthetic peptide / analogue
- Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression ↗
2013 · Review
Tireogen ↗
Named tissue preparation · Tissue extract
2 human reports
The report describes symptom and thyroid-hormone changes during adjunctive care.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Tireogen: institute clinical report (commercially hosted translation) ↗
2006 · Institute report — commercial reproduction · Tissue-derived mixture / named preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
25 treated patients and 19 controls with primary hypothyroidism; report dates November 2005–January 2006
The report describes symptom and thyroid-hormone changes during adjunctive care.
- Tireogen and Endoluten as adjuncts in autoimmune thyroiditis ↗
2017 · Published conference abstract with author report · Oral Tireogen, or Tireogen plus Endoluten, alongside standard treatment
218 adults aged 39–51: 89 standard treatment, 42 standard treatment plus Tireogen, 87 standard treatment plus Tireogen and Endoluten.
At four months the author table reports TSH of 7.14 with standard care, 4.09 with adjunctive Tireogen, and 3.94 mIU/L with the combination. Antibody findings are reported with inconsistencies between table and narrative.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
Ventfort ↗
Named tissue preparation · Tissue extract
4 human reports
The 2005–2006 report describes lipid and capillary-fragility outcomes during 10–15 days of adjunctive care.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Ventfort: clinical report on a tissue-derived preparation ↗
2006 · Institute report — commercial reproduction · Tissue-derived mixture / named preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
49 patients: 27 adjunctive Ventfort; 22 controls; ages 52–84, atherosclerosis or senile purpura.
The 2005–2006 report describes lipid and capillary-fragility outcomes during 10–15 days of adjunctive care.
- Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration ↗
2021 · Original journal report · Temporal paravascular Retinalamin injections with or without Cortexin and Ventfort Lingval by electrophoresis
38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.
Visual acuity went from 0.71 to 0.76 with Retinalamin alone and from 0.76 to 0.88 with the combination. This comparison used electrophoresis for the two added preparations.
2 more studies
- Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis ↗
2013 · Conference report · company reproduction · Oral vascular, brain, liver and pineal polypeptide preparations added to standard therapy
1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.
The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.
- Oral peptide combinations for prostate symptoms in Agent Orange-exposed veterans ↗
2012 · Uncontrolled human report · Veziliut, Vezugen, Kristagen and Ventfort as named in the paper. Branded oral preparations.
150 veterans with benign prostatic hyperplasia. The same 150 are shown before and after treatment.
In 150 veterans, mean prostate symptom score (IPSS) fell from 20.94 to 8.46 (p<0.01) and urinary flow increased from 4.9 to 9.1 mL/s (p<0.001). This before-and-after comparison tested four oral products together.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
Composition, reviews & other sources (1)
- Ventfort plus Chonsurid: dental bone-healing method — RU2593817C2 ↗
2016 · Patent publication · Patent-defined substance or composition
Ventvil ↗
Liver · Tissue extract
1 animal models · 2 cell / tissue models
At 96 hours the table lists a liver-cell mitotic index of 4.850 for treatment versus 2.012 for saline after surgery. The same values appear in an earlier patent that attributes them to injected synthetic EDL and reports a different animal count and dose.
Studies and sources
Sequence or preparation · Mixture
Related preparation · Liver-derived complex. Separate from Livagen/KEDA and Ovagen product claims.
Animal models
- Injected Ventvil after partial liver removal in rats ↗
2012 · Original journal article · Experimental calf-liver extract, peptide fractions up to 5 kDa, injected subcutaneously.
28 male rats assigned to four groups. Total enrollment is given without arm or time-point counts.
At 96 hours the table lists a liver-cell mitotic index of 4.850 for treatment versus 2.012 for saline after surgery. The same values appear in an earlier patent that attributes them to injected synthetic EDL and reports a different animal count and dose.
Cell / tissue models
- [POLYPEPTIDES INFLUENCE ON TISSUE CELL CULTURES REGENERATION OF VARIOUS AGE RATS]. ↗
2015 · Original journal report
Organotypic tissue cultures from young and old rats
Calf-tissue preparations, including Ventvil, stimulated corresponding tissue-culture growth with changes in proliferation-related markers.
- Combined effect of polypeptide complexes on organotypic rat tissue cultures ↗
2023 · Original journal article · Organ-derived polypeptide preparations applied directly to rat tissue in culture.
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences
Three-month-old Wistar rats supplied explants. Methods report 280 liver, 300 spleen and 250 kidney explants. Donor rat count is unspecified.
At 20 ng/mL, Ventvil increased the liver explant area index by 21 ± 5% versus medium alone (17 explants). Ventvil plus Thymalin gave a 20 ± 3% increase (21 explants). Ventvil alone had no significant effect in spleen explants.
Two placebo-controlled injection registrations are available. Outcome and safety data remain unavailable.
Composition, reviews & other sources (3)
- Ventvil Phase I injection safety trial registration (HEP-VTL-01) ↗
2017 · Clinical trial registration · Investigational intramuscular Ventvil liver polypeptide complex.
- Ventvil Phase II placebo-controlled liver disease trial registration (VNT-08-2018) ↗
2019 · Clinical trial registration · Ventvil 5 mg lyophilizate for intramuscular injection, manufactured by Samson-Med.
1 more sources
- The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology ↗
2020 · Review
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Vesugen ↗
Vessels · Synthetic peptide
9 human reports · 2 animal models · 5 cell / tissue models
Clinical and ultrasound blood-flow improvement was reported after Vezugen treatment; the abstract supplies no numerical effect estimate.
Studies and sources
Sequence or preparation · KED
Related preparation · Vessel complex / Vasolin. KED detected in vessel complex. The sequence and branded formulations are separate identity questions.
Human reports
- Vezugen in postoperative chronic lower-limb arterial insufficiency ↗
2013 · Original clinical journal publication · Vezugen; exact formulation/sequence not established by abstract
41 postoperative patients with chronic lower-limb ischemia
Clinical and ultrasound blood-flow improvement was reported after Vezugen treatment; the abstract supplies no numerical effect estimate.
- Vesugen in vasculogenic erectile dysfunction and lower-limb arterial disease ↗
2014 · Journal publication · Synthetic peptide / defined-sequence research
41 men with atherosclerosis, lower-limb ischemia and vascular erectile dysfunction. Vesugen 26, untreated comparison 15. Recruitment January 2009 to July 2010.
At one month, peak systolic velocity in the dorsal penile artery was about 26.3 vs 16.3 cm/s with Vesugen versus untreated comparison. Figure values are approximate.
7 more studies
- The peptide correction of neurotic disorders among professional truck-drivers ↗
2012 · Human comparative study · Pinealon and Vezugen peptide bioregulators, including combined use. The abstract does not specify the dosage form.
150 male lorry drivers and 150 male metal craftsmen in the occupational comparison
The abstract describes occupational psychoemotional differences and reports changes with peptide bioregulators, including combined Pinealon and Vezugen.
- Vesugen — originating-institute clinical report ↗
Institute report / commercial reproduction · Marketed product / formulation not independently verified
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
40 patients with atherosclerosis, ages 54–77. Vesugen plus conventional care: 25. Conventional care: 15. Enrollment ran from November 2005 to February 2006.
In a 40-patient report, mean post-treatment total cholesterol was 6.4 mmol/L with Vesugen plus conventional care and 7.0 mmol/L with conventional care alone. The report gives one shared baseline column.
- Personified prevention of diseases under the conditions of the Far North ↗
2016 · Journal publication · Risk-assigned capsule program: Endoluten tissue extract and named synthetic peptide products; Cerluten also named in assignments
113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.
- Oral peptide combinations in Agent Orange-exposed veterans with immune deficiency ↗
2013 · Uncontrolled human report · Vladoniks, Vezugen and Kristagen as named in the paper. Branded oral preparations.
150 veterans with immune deficiency in the Joint Vietnam–Russia Program 33. The same 150 are shown before and after treatment.
In 150 veterans, mean IgG rose from 1,202.27 to 1,445.20 mg/dL and CD4 cells from 501.96 to 569.33 cells/µL (both p<0.01). CD19 and the CD4/CD8 ratio did not change significantly.
- Oral peptide combinations for prostate symptoms in Agent Orange-exposed veterans ↗
2012 · Uncontrolled human report · Veziliut, Vezugen, Kristagen and Ventfort as named in the paper. Branded oral preparations.
150 veterans with benign prostatic hyperplasia. The same 150 are shown before and after treatment.
In 150 veterans, mean prostate symptom score (IPSS) fell from 20.94 to 8.46 (p<0.01) and urinary flow increased from 4.9 to 9.1 mL/s (p<0.001). This before-and-after comparison tested four oral products together.
- Oral Pinealon and Vesugen in older men: four-arm randomized comparison ↗
2010 · Dissertation author abstract · Branded oral Pinealon (EDR) and Vesugen (KED) capsules. The report does not specify the peptide mass per capsule.
170 men aged 60–74. Pinealon 43, Vesugen 45, both 42, Decamevit multivitamin control 40.
After 30 days, working-memory scores were 17.4 with Pinealon, 17.8 with Vesugen and 17.5 with both, versus 12.4 with multivitamins. The combination had the largest change on the composite severity index. At five-month follow-up, the figure marks a baseline difference only for that index in the combination arm.
- [EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION]. ↗
2015 · Uncontrolled human report
Adults aged 41–83 with multiple conditions and organic brain syndrome in remission
The authors reported changes in biological-age indicators after Pinealon and Vesugen. They also reported prooxidant activity and lower circulating CD34-positive cell markers.
Animal models
- Investigation of antihypoxic properties of short peptides ↗
2008 · Journal publication · Synthetic peptide / defined-sequence research
Experimental hypobaric/prenatal hypoxia models
The comparative report describes antihypoxic activity, with the largest effect for Pinealon in the tested model.
- Pinealon after maternal hypoxia: offspring and adult-rat findings ↗
2008 · Original journal publication · Pinealon in maternal arm; separate adult-male Vilon, Vesugen, Pinealon and Epitalon arms
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Pregnant rats exposed to hypoxia on gestation day 10; separate adult-male experiment, n=10/group; offspring open-field strata n=6, 11, 9 and 12
Pinealon-treated hypoxic dams had 14±2 offspring versus 9±3 with saline (p<0.05). Offspring activity and neuronal responses changed. Adult-rat Table 1 reports 10% mortality with both Pinealon and saline, conflicting with the narrative claim of higher Pinealon mortality.
Cell / tissue models
- Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro ↗
2016 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Aging skin-fibroblast cultures; KE, KED, AED and AEDG
The peptides altered proliferation, remodeling and aging-associated protein markers. AED and AEDG also reduced caspase-dependent apoptosis in this model.
- Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides ↗
2020 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Human embryonic bone-marrow MSC line FetMSCs, aged in culture
AED, KED and KE changed expression of selected aging-related genes. Effects depended on peptide and culture-aging model; KED affected TNKS2 in opposite directions across models.
3 more studies
- Peptides tissue-specifically stimulate cell differentiation during their aging ↗
2012 · Journal publication · Defined synthetic peptides
Human embryonic pancreatic and bronchial cell cultures, plus human prostatic fibroblasts, compared at different passage ages.
Pancragen increased differentiation-marker expression in pancreatic cells, Bronchogen in bronchial cells, and Vesugen in prostatic fibroblasts. Responses were more pronounced in aged cultures.
- Biological activity of regulatory peptides in model experiments in vitro ↗
2008 · Journal publication · Synthetic peptide / defined-sequence research
Lipoprotein, erythrocyte and neuronal model experiments
The peptides did not behave as direct antioxidants. Effects on lipid peroxidation, membrane stability and neuronal survival differed by peptide.
- Effect of short peptides on neuronal differentiation of stem cells ↗
2019 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Human periodontal-ligament stem-cell cultures
Examined AED, KED, KE, AEDG and their mixture. Increased neuronal-marker expression was reported for KED and the mixture.
Separate 2013 lower-limb report and 2014 erectile-dysfunction publication; cohort overlap unresolved. PMID 25051774 has a title/abstract mismatch. Institute product and combination reports do not isolate purified KED.
Composition, reviews & other sources (7)
- Identification of short peptides in the composition of polypeptide complexes isolated from animal organs ↗
2020 · Analytical / composition study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
- Peptidergic regulation of age-related alterations in the cardiovascular system ↗
2026 · Journal publication
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
5 more sources
- Vesugen plus Chonsurid: dental bone-healing method — RU2582976C1 ↗
2016 · Patent publication · Patent-defined substance or composition
- Vesugen: salivary-function adjunctive method — RU2554504C1 ↗
2015 · Patent publication · Patent-defined substance or composition
- KED / Vesugen: defined peptide and microcirculation claims — US7851449B2 ↗
2010 · Patent publication · Patent-defined substance or composition
- Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation ↗
2023 · Review
- Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression ↗
2013 · Review
Vilon ↗
Thymus / immunity · Synthetic peptide
4 human reports · 3 animal models · 10 cell / tissue models
After 20 days, 87/270 Epimental recipients and 211/290 placebo recipients reported disturbed sleep. In the separate Regevil comparison, 110/276 and 200/244, respectively, reported fatigue.
Studies and sources
Sequence or preparation · KE
Related preparation · Thymalin. Composition paper identifies KE in the extract; detection does not establish equivalence.
Human reports
- Oral Epitalon for prolonged stress and Vilon during recovery from infection: two placebo comparisons ↗
2021 · Journal report of two placebo comparisons · Epimental (Epitalon, AEDG) and Regevil (Vilon, KE), tested separately as oral supplements.
Author affiliations · Academy of Postgraduate Education, Federal Research and Clinical Center, Federal Biomedical Agency, Moscow · St. Petersburg Institute of Bioregulation and Gerontology
Epimental: 560 adults aged 35–68 after prolonged occupational or emotional stress, including time-zone changes (270 active, 290 placebo). Regevil: 520 adults aged 43–76 recovering from acute respiratory, bacterial or viral illness (276 active, 244 placebo).
After 20 days, 87/270 Epimental recipients and 211/290 placebo recipients reported disturbed sleep. In the separate Regevil comparison, 110/276 and 200/244, respectively, reported fatigue.
- Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus ↗
2007 · Journal publication · Synthetic peptide / defined-sequence research
Type-1 diabetes patients receiving adjunctive care
Adjunctive Vilon in type 1 diabetes was associated with immune and coagulation-marker changes, including antithrombin III, protein C and fibrinolysis. No autoimmune disease-modifying effect is established.
2 more studies
- Effect of thymomimetic vilon on blood coagulation system and fibrinolisis in diabetes mellitus type 1 patients of different age ↗
2006 · Journal publication · Synthetic peptide / defined-sequence research
Type-1 diabetes patients of different ages
The abstract reports coagulation and fibrinolysis changes during adjunctive Vilon treatment in type 1 diabetes, with weaker responses in older patients with severe disease. These are surrogate outcomes.
- Thymalin, Epithalamin and Vilon after complicated appendicitis ↗
2008 · Original clinical journal article
Author affiliations · Chita Medical Institute
84 adults aged 18–42: 12 with uncomplicated appendicitis and 72 with postoperative wound infection. Of the 72, 62 received a peptide adjunct. Thirty healthy volunteers were a laboratory reference group.
Mean hospital stay was 24.2 days with standard care and 18.0–19.0 days in the four adjunct groups. TNF-α fell most in the Vilon cytokine subset. IL-8 increased in every measured group.
Animal models
- Investigation of antihypoxic properties of short peptides ↗
2008 · Journal publication · Synthetic peptide / defined-sequence research
Experimental hypobaric/prenatal hypoxia models
The comparative report describes antihypoxic activity, with the largest effect for Pinealon in the tested model.
- Age and baseline anxiety in Lysenko’s peptide stress models ↗
2006 · Doctoral dissertation, 244 pp., introduction and conclusions
Rats grouped by age and baseline anxiety; series-specific denominators remain unverified.
The author reported that the direction of peptide-associated changes depended on age and baseline anxiety. Some shifts were unfavorable.
1 more studies
- Pinealon after maternal hypoxia: offspring and adult-rat findings ↗
2008 · Original journal publication · Pinealon in maternal arm; separate adult-male Vilon, Vesugen, Pinealon and Epitalon arms
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Pregnant rats exposed to hypoxia on gestation day 10; separate adult-male experiment, n=10/group; offspring open-field strata n=6, 11, 9 and 12
Pinealon-treated hypoxic dams had 14±2 offspring versus 9±3 with saline (p<0.05). Offspring activity and neuronal responses changed. Adult-rat Table 1 reports 10% mortality with both Pinealon and saline, conflicting with the narrative claim of higher Pinealon mortality.
Cell / tissue models
- Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro ↗
2016 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Aging skin-fibroblast cultures; KE, KED, AED and AEDG
The peptides altered proliferation, remodeling and aging-associated protein markers. AED and AEDG also reduced caspase-dependent apoptosis in this model.
- Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides ↗
2020 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Human embryonic bone-marrow MSC line FetMSCs, aged in culture
AED, KED and KE changed expression of selected aging-related genes. Effects depended on peptide and culture-aging model; KED affected TNKS2 in opposite directions across models.
8 more studies
- Effects of short peptides on lymphocyte chromatin in senile subjects ↗
2004 · Journal publication · Defined synthetic peptides
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Leukocytes sampled from people aged 75–88 years and exposed to peptides in culture.
Five short peptides increased ribosomal-gene activity and altered condensed chromatin in sampled leukocytes. Epitalon, Livagen and Prostamax changed chromosome-1 pericentromeric chromatin; Epitalon and Livagen also changed chromosome 9.
- Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line ↗
2022 · Journal publication · Defined peptides and Thymalin peptide complex tested separately
THP-1 leukemia-derived monocytes, differentiated macrophages and an activated HUVEC endothelial adhesion model.
Five preparations reduced LPS-induced TNF and IL-6 expression in differentiated THP-1 cells and reduced adhesion to activated endothelial cells. Chonluten also reduced monocyte TNF release; the full text notes an apoptotic cell fraction with Chonluten.
- Vilon and R-1 in cultured human and rat thymic cells ↗
2013 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Cultured human and rat thymic cells. Donor and replicate counts are unavailable in the abstract.
Vilon and its R-1 analogue both increased CD5 expression. Vilon promoted CD4 T-helper differentiation more weakly than R-1.
- Vladonix, Endoluten and other peptides in cultured human blood cells ↗
2016 · Original journal article · Six separately assayed peptide preparations supplied by the Khavinson laboratory.
Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.
Vladonix increased cell-lysate IL-18 to a median of 66.48 vs 39.06 pg/mL with saline and lowered IL-1RA to 3,765 vs 5,228 pg/mL. The study compared six preparations in cell culture.
- Epitalon and Vilon in rat pinealocyte culture ↗
2012 · In vitro
Cultured rat pinealocytes.
The abstract reports increased AANAT and phosphorylated CREB and higher culture-medium melatonin with Epitalon. It describes stronger marker expression when norepinephrine was added with the peptides.
- Effects of short peptides on thymocyte blast transformation and signal transduction along the sphingomyelin pathway. ↗
2002 · Original journal report
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Mouse thymocytes
Vilon stimulated thymocyte proliferation most strongly; Epitalon was less active and Cortagen showed no such effect.
- Biological activity of regulatory peptides in model experiments in vitro ↗
2008 · Journal publication · Synthetic peptide / defined-sequence research
Lipoprotein, erythrocyte and neuronal model experiments
The peptides did not behave as direct antioxidants. Effects on lipid peroxidation, membrane stability and neuronal survival differed by peptide.
- Effect of short peptides on neuronal differentiation of stem cells ↗
2019 · In vitro
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Human periodontal-ligament stem-cell cultures
Examined AED, KED, KE, AEDG and their mixture. Increased neuronal-marker expression was reported for KED and the mixture.
Adjunctive diabetes reports may overlap. The longevity studies used tissue extracts.
Composition, reviews & other sources (8)
- Identification of short peptides: optimization of target therapeutic properties of the thymus medicine ↗
2021 · Analytical / composition study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
- Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process ↗
2014 · Journal publication · Short-peptide experimental preparations; marketed-product equivalence unresolved
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
6 more sources
- From thymus extracts to synthetic thymomimetics ↗
2026 · Narrative review
- Normophthal / Lys-Glu: ocular angiogenesis use — RU2177801C1 ↗
2002 · Patent publication · Patent-defined substance or composition
- Vilon: Lys-Glu and reparative-process claims — RU2139085C1 ↗
1999 · Patent publication · Patent-defined substance or composition
- Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results ↗
2013 · Review
- Short Peptides Regulate Gene Expression ↗
2016 · Computational mechanism study
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
- Mechanism of Biological Activity of Short Peptides: Cell Penetration and Epigenetic Regulation of Gene Expression ↗
2013 · Review
Sources with open questions (1)
- Vilon: surgery, thermal trauma and macular-degeneration studies ↗
Lead · original evidence not verified
Vilosen ↗
Immune research · Tissue extract
3 human reports · 1 animal models
The report describes immune abnormalities in 163 asthma patients and improvement with adjunctive Vilosen in atopic-associated asthma. It supplies no treated-arm denominator or numerical symptom response.
Studies and sources
Sequence or preparation · Thymus-derived preparation; not a single defined sequence
Related preparation · Historical thymus-preparation research. Vilosen, Vilon, Tactivin and Thymalin are distinct preparations.
Human reports
- The effect of vilozen on the immune status of bronchial asthma patients ↗
1990 · Journal publication · Native nonprotein animal-thymus extract; not synthetic Vilon
163 bronchial-asthma patients underwent immune assessment; the abstract does not specify how many received Vilosen.
The report describes immune abnormalities in 163 asthma patients and improvement with adjunctive Vilosen in atopic-associated asthma. It supplies no treated-arm denominator or numerical symptom response.
- The immunomodulating effect of vilozen and splenin in the treatment of patients with acute and chronic toxic-allergic hepatitis ↗
1993 · Journal publication · Thymus extract plus separate spleen-derived preparation
65 acute and 116 chronic toxic-allergic hepatitis patients examined; 20 acute and 40 chronic patients received add-on Vilosen plus Splenin.
Vilosen plus Splenin was reported to speed clinical and immune normalization when added to usual hepatitis treatment. Of 181 patients assessed, 60 are explicitly described as receiving the combination.
1 more studies
- The efficacy of immunomodulating therapy in patients with chronic cholestatic liver diseases ↗
1996 · Journal publication · Thymus extract combined with Splenin
93 patients with chronic cholestatic liver disorders; combined Splenin/Vilosen treatment.
The combined extract regimen was associated with improved immune and microcirculatory measures and longer remission in chronic cholestatic liver disease. The abstract gives no remission duration or response percentage.
Animal models
- [Radiation protective effect of low molecular weight thymus preparations]. ↗
1994 · Animal / experimental · Preparation-specific research; no equivalence inferred
See original report; human, animal and laboratory components must be distinguished.
The abstract discusses low-molecular-weight thymic preparations in radiation injury; it does not provide enough methods to establish a human controlled study.
Historical adjunctive reports do not isolate an extract effect. Read the source-specific formulation, comparator and numerical outcomes.
Visoluten ↗
Named tissue preparation · Tissue extract
1 human reports
The report describes visual-acuity and retinal electrophysiology changes during adjunctive care.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Visoluten: institute clinical report (commercially hosted translation) ↗
2011 · Institute report — commercial reproduction · Tissue-derived mixture / named preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
49 patients: 29 adjunctive preparation, 20 conventional-care controls
The report describes visual-acuity and retinal electrophysiology changes during adjunctive care.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
Vladonix ↗
Named tissue preparation · Tissue extract
3 human reports · 1 cell / tissue models
In the 24-person moderate-disease comparison, Table 1 reports mean illness duration of 14 vs 16 days and post-COVID symptoms in 3 of 12 vs 7 of 12 patients with combination treatment versus standard care.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Vladonix with recombinant IL-2 and interferon in COVID-19 outpatients ↗
2022 · Original journal article · Oral Vladonix A-6 thymus peptide complex, given with injectable recombinant IL-2 and intranasal interferon in the acute moderate branch.
48 PCR-confirmed outpatients aged 18–50 in Almaty and Semey, Kazakhstan. Mild and moderate disease each had 12 adjunct-treatment and 12 standard-care patients.
In the 24-person moderate-disease comparison, Table 1 reports mean illness duration of 14 vs 16 days and post-COVID symptoms in 3 of 12 vs 7 of 12 patients with combination treatment versus standard care.
- Vladonix: clinical report on a tissue-derived preparation ↗
2006 · Institute report — commercial reproduction · Tissue-derived mixture / named preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
76 patients: 42 adjunctive Vladonix; 34 controls. Prior low-dose radiation exposure or radiation/chemotherapy.
In the 76-person institute report, CD4-positive cells were 34.6% after adjunctive oral Vladonix and 30.8% after usual care, compared with a shared 28.5% baseline column.
1 more studies
- Oral peptide combinations in Agent Orange-exposed veterans with immune deficiency ↗
2013 · Uncontrolled human report · Vladoniks, Vezugen and Kristagen as named in the paper. Branded oral preparations.
150 veterans with immune deficiency in the Joint Vietnam–Russia Program 33. The same 150 are shown before and after treatment.
In 150 veterans, mean IgG rose from 1,202.27 to 1,445.20 mg/dL and CD4 cells from 501.96 to 569.33 cells/µL (both p<0.01). CD19 and the CD4/CD8 ratio did not change significantly.
Cell / tissue models
- Vladonix, Endoluten and other peptides in cultured human blood cells ↗
2016 · Original journal article · Six separately assayed peptide preparations supplied by the Khavinson laboratory.
Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.
Vladonix increased cell-lysate IL-18 to a median of 66.48 vs 39.06 pg/mL with saline and lowered IL-1RA to 3,765 vs 5,228 pg/mL. The study compared six preparations in cell culture.
Oral Vladonix was one component of the moderate COVID-19 regimen. The cytokine paper tested direct exposure of cultured cells.
Zhenoluten ↗
Named tissue preparation · Tissue extract
2 human reports
The report describes symptom and hormone changes during adjunctive treatment.
Studies and sources
Sequence or preparation · Tissue-derived mixture; current-product equivalence unresolved
Related preparation · Preparation-specific institute report. The report identifies the tissue-derived product by name.
Human reports
- Zhenoluten: institute clinical report (commercially hosted translation) ↗
2011 · Institute report — commercial reproduction · Tissue-derived mixture / named preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
67 women: 39 with climacteric symptoms and 28 with early ovarian insufficiency; four comparison groups
The report describes symptom and hormone changes during adjunctive treatment.
- Zhenoluten and Endoluten in women with reduced reproductive function ↗
2019 · Conference report and expanded author report · Oral ovarian and pineal polypeptide combination
276 women aged 34–38: 214 received the peptide combination and 62 received placebo.
In the 276-person comparison, anti-Müllerian hormone was 1.16 versus 0.82 ng/mL after four months. The expanded report also lists 180/214 versus 8/62 pregnancies, with limited detail on allocation and follow-up.
The clinical report appears in a commercial reproduction. Allocation and masking are generally unspecified.
Tissue-family research ↗ Clinical reports on tissue preparations ↗ Bibliography & PDFs ↗